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Abstract 
A foundation of modern diagnostics and therapeutics is the ability to non-covalently bind 
to a molecule of interest. These affinity molecules are behind a broad array of products 
ranging from therapeutics to HIV tests. Currently, antibodies are used as the affinity 
molecule. Despite the success of antibodies, alternatives are needed due to high 
development and production costs, and issues with stability. Aptamers are an exciting 
alternative to antibodies. Aptamers are short sequences of single stranded DNA or RNA 
that bind molecular targets with high affinity and specificity. Aptamers are inexpensive to 
produce, are very stable, have long shelf lives, and could potentially replace antibodies in 
a number of applications. One potential application of aptamers is targeted drug delivery. 
The goal of targeted drug delivery is to selectively deliver a therapeutic payload to the site 
of action thereby increasing efficacy and decreasing side effects. Fractalkine is a cell 
surface protein expressed at sites of inflammation. It is expressed on several types of 
cancerous tissues and it is involved in the patheogenisis of arthritis, asthma, and 
atherosclerosis. This work describes the development and characterization of an aptamer 
that binds fractalkine with high affinity. The aptamer was modified with a hydrophobic tail, 
creating an aptamer-amphiphile, for use in a model drug delivery vesicle called a 
liposome. The aptamer-amphiphile was optimized for a high affinity interaction with 
fractalkine by adding a spacer molecule between the aptamer headgroup and the 
hydrophobic tail. The optimized amphiphile had high affinity for fractalkine and self-
assembled into micelles and an interesting nanotape morphology. Finally, as a proof of 
concept, the optimized aptamer-amphiphile was incorporated into a liposome and targeted 
to fractalkine expressing cells. This work highlights the development of aptamers as 
affinity ligands, and demonstrates their use as potential drug delivery agents. 
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1 Introduction 
The ability to bind molecules is an essential tool in modern science, especially in biological 
and medical disciplines.1, 2 These molecular recognition tools specifically bind to target 
molecules through non-covalent interactions. Antibodies are the most widely used 
molecular detection ligand and have been used for decades in therapeutics, sensors, 
diagnostic tests, and imaging agents with great success.3 However, there is a drive to 
develop antibody alternatives that maintain the high affinity binding to the target molecules 
but have properties better suited for the particular application.1, 4   
 
Aptamers are an alternative molecular detection ligand made of single stranded DNA or 
RNA.5-9 Aptamers have potential uses in sensors and diagnostic assays,9, 10 affinity 
separations,11 imaging, and drug delivery applications.6, 12-16 Even though they were 
discovered in the 1990’s, a significant amount of research is needed before aptamers are 
ready for commercial applications primarily because antibodies are well studied and 
developed.1 This work investigates the development, modification, and characterization of 
an aptamer that binds a cell surface protein called fractalkine, and uses the aptamer as a 
ligand for targeted drug delivery.  
 
 
1.1 Aptamers 
 
1.1.1 What are aptamers 
Aptamers are sequences of single stranded DNA (ssDNA) or RNA that bind to a specific 
molecule. Although typically short, 15-60 nucleotides in length, aptamers fold into complex 
three-dimensional structures either in free solution or upon binding to the target 
  2 
molecule.17 The complex shape allows the aptamer to strongly interact with the target 
molecule through hydrogen bonding, base stacking, van der Waals forces, and 
electrostatic interactions to produce a high affinity interaction.  
 
At first thought, it seems strange that ssDNA can bind molecular targets. We typically think 
of DNA as a passive carrier of genetic information. However, this is a naive viewpoint. Not 
only do nucleic acids interact with and bind proteins with in the cell, they are active 
members of the cellular arsenal being involved in protein synthesis (ribosomes), mRNA 
splicing (splicesomes), and protein regulation (riboswitch).18 It was the discovery of this 
active role of RNA that led to the discovery of aptamers in the early 1990s by three 
independent groups with the Szostak and Gold labs developing in vitro selection 
techniques.19-21  
 
Aptamers can be either RNA based or DNA based. Some have suggested RNA aptamers 
may be better binders than DNA aptamer because the increased flexibility of RNA allows 
for more complex folding.1, 13, 22 However, most often there is little to no difference between 
DNA aptamers and RNA aptamers except that DNA is inherently more stable.8, 22 Several 
DNA and RNA aptamers have been selected against the same target molecule like 
thrombin,23-25, interferon ɣ,26, 27 and immunoglobulin E.28, 29 DNA and RNA aptamers are 
typically not interchangeable; an RNA aptamer that is converted to DNA usually does not 
bind. However, there are cases where DNA and RNA aptamers with the same sequence 
do bind the same target.30-32 Certain structural motifs may translate well between the 
nucleic acids while others do not.32  
 
  3 
Aptamers are widely touted as antibody alternatives and are used in applications such as 
sensors and diagnostic assays,9, 10 affinity chromatography,11, 16 and therapeutic and 
imaging agents.6, 12-15 Antibodies are currently the dominant molecular detection ligand 
used for therapeutics and diagnostics. However, aptamers are well suited in many 
applications where antibodies are currently used, and present several advantages to 
antibodies. 
 
 
1.1.2 Advantages and drawbacks of aptamers 
Affinity and specificity are important properties of any binding ligand like antibodies or 
aptamers. Affinity is a measure of how strongly the ligand binds its target molecule. It is 
quantified by the equilibrium dissociation constant (KD). Aptamers have affinities that are 
similar to those of antibodies, varying from the low micromolar to picomolar, with the low 
nanomolar affinities being typical.10, 33 Specificity is the preferential binding to the target 
molecule over similar molecules.34 Aptamers are highly specific molecules. They can 
distinguish between isozymes,35, 36 molecules differing by a single functional group,37, 38 
and even enantiomers.39, 40 Perhaps the best known example of specificity is an aptamer 
that was designed to bind theophylline but not caffeine. Theophylline and caffeine differ in 
structure by a single methyl yet the aptamer has a 10,000 fold difference in affinity between 
the two molecules.41  
 
A major advantage of aptamers is the in vitro identification process.7 Antibodies are often 
made though the immunization of animals. The target molecule, the antigen, is injected 
into an animal resulting in an immune response. The immune system develops antibodies 
against the antigen and those antibodies are collected (to make poly-clonal antibodies) or 
  4 
the spleen is harvested and the antibody producing cells are hybridized to produce a 
monoclonal antibody cell line. The process is typically done in vivo. Aptamer selection, on 
the other hand, is done in vitro. Because of this, aptamers can be selected against 
molecules that are poorly immunogenic.13 Target molecule include small ions like Zn+,42 
small molecules,43, 44 proteins,23, 45 carbohydrates,46, 47 toxins,48, 49 and even whole 
organisms like bacteria and viruses.50-52 However aptamers selected against small 
molecules tend to have lower affinity because of fewer target-aptamer interactions.3 In 
vitro selections also allow the aptamer binding conditions to be optimized to the intended 
application. Buffers, salt concentrations, temperature, pH, and organic solvent content 
affect the binding affinity of ligands. With aptamers, the in vitro selection procedure can 
mimic the conditions in the intended application.53 Aptamers have been selected to 
tolerate high concentrations of organic solvents (20% methanol) where antibodies failed 
to bind.54 Similarly, an aptamer was developed for affinity chromatography that retained 
activity in a mobile buffer phase containing 30% acetonitrile.55 
 
In addition to the in vitro selection process, aptamers are synthesized chemically unlike 
antibodies which are produced in vivo or in bioreactors. Because of the cellular origins, 
the production of antibodies is highly variable. Changes in the secondary and tertiary 
structure, glycosylation patterns, and drug-antibody conjugation efficiency, biological 
function can vary considerably from batch to batch. This makes regulating the production 
of antibodies for therapeutic use difficult requiring multiple assays to ensure proper 
biological activity. The glycosylation patterns require the use of mammalian cell lines for 
production greatly increasing the costs.1 Aptamers, on the other hand, are synthesized 
chemically. This significantly reduces the cost of production because mammalian cell 
  5 
culture is avoided. It also increases the consistency. There is little batch to batch variation. 
And the chemical synthesis allows for easy and site specific modifications at the 5’ or 3’ 
ends of the aptamer, but also within the aptamer strand itself.7, 56, 57  
 
The relative simplicity of aptamers serves both as an advantage and disadvantage. 
Aptamers are composed of just 4 building blocks, adenine, guanine, cytosine and 
thymine/uracil while antibodies are built from 20 amino acids. Antibodies are large 
proteins, around 150 kDa, with a complex tertiary structure and glycosylation patterns. 
Aptamers, while they do form complex shapes, are much less complex than the intricate 
folding required of antibodies. Aptamers can be denatured like antibodies by heat, pH, 
and chemical solvents. However, unlike antibodies, aptamers undergo reversible 
denaturation. Aptamers are refolded by heating the aptamer above its melting temperature 
in the appropriate buffer and cooling to room temperature. This reversible denaturation, 
along with the chemical stability of nucleic acids, especially DNA, greatly extends the shelf 
life of the aptamer. Aptamers stored as lyophilized or dried powder have a shelf life of 
decades.  
 
This simplicity also limits aptamers. Some molecular targets, especially negatively 
charged proteins, evade aptamer selection.58 This is likely because there are only 4 base 
options compared to the 20 for antibodies limiting the chemical diversity to interact with 
the target molecule.59 To overcome this, several alternative or modified bases have been 
developed.56, 60 These modified bases have enabled aptamers to bind targets that 
previously avoided selection.61  
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1.1.3 Aptamers and the structure of DNA 
Aptamers form complex three dimensional shapes and this shape is essential to the target 
affinity and specificity.17 Aptamers also form several secondary structures that influence 
binding like step-loops, pseudoknots, and G-quadruplex structures.4 Furthermore, the 
aptamer interacts with the target molecule through a variety of forces including van der 
Waals forces, hydrogen bonding, aromatic stacking interactions, and electrostatic forces. 
The structure of DNA is essential in understanding these interactions. 
 
DNA and RNA are a linear biopolymers of repeating adenine (A), thymine (T), cytosine 
(C), guanine (G) and uracil (U) nucleobases connected though a sugar-phosphate 
backbone. Figure 1.1 shows the structures of the nucleobases. The bases are derivatives 
of pyrimidines (C, T, U) and purine (A, G). The bases are attached to a sugar molecule, 
deoxyribose for DNA and ribose for RNA, though a β-glycosidic linkage. The structure of 
deoxyribose is shown in Figure 1.2. In RNA, the 2’ hydrogen is replaced with an –OH 
group. The nucleobases are attached at the 1’ position to form a nucleoside. The 
nucleosides are joined by a phosphodiester linkage through the 5’ and 3’ positions of the 
sugar. The structure of DNA is shown in Figure 1.3. The two major forces between DNA 
strands are hydrogen bonding and aromatic base stacking.62 Hydrogen bonding occurs 
between the bases to form the traditional Watson-Crick base paring, A to T and C to G. 
However, alternative base paring is also possible.63, 64 
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Figure 1.1: Structures of the nucleobases with the carbon atoms numbered. The base 
attaches to the ribose sugar through C9 for Adenine and Guanine and C3 for cytosine, 
thymine, and uracil. 
 
 
 
Figure 1.2: Structure of the deoxyribose sugar that makes up DNA. RNA is made from a 
similar sugar except the 2’ hydrogen is replaced with an -OH group. The carbons are 
labeled with primes to distinguish from the nucleobase carbons.  
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Figure 1.3: Structure of DNA with each nucleoside. The DNA strands have a directionality 
based on the 5’ and 3’ phosphodiester bonds.  
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1.1.4 Secondary structure of DNA 
Nucleic acids can adopt a variety of secondary and tertiary structures. Perhaps the most 
well known, however, is the double helix. The DNA double helix forms when two 
complimentary strands of DNA pair together with one strand running in the 5’ to 3’ direction 
and the other strand running in the 3’ to 5’ direction.64 The bases interact through Watson-
Crick base pairing and base stacking. Each base pair is offset from the pair above giving 
rise to the helical structure of the double stranded DNA. Double stranded DNA can occur 
in several different conformations. Only three conformations, A-form, B-form, and Z-form, 
have been observed in nature with the majority of double stranded DNA taking the B-
form.65, 66 B-form DNA, first characterized by Watson and Crick, forms a right handed 
double helix with a strand diameter of 2 nm and a complete rotation of the helix 
approximately every 10 base pairs or 3.4 nm of strand length.64 
 
1.1.5 Stem-loop structure 
The stem-loop structure, also known as a hairpin structure, is one of the most common 
secondary structures found in DNA and RNA. Stem-loop structures occur when 
complementary sequences within a single DNA or RNA strand hybridize forming a double 
stranded stem region, and a single stranded loop region where the nucleic acid folds on 
itself and reverses direction.67 Figure 1.4 is a diagram of a stem-loop structure. The base 
paring in the stem portion is in the double helix B-form conformation.68 
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Figure 1.4: Diagram of a stem-loop structure. 
 
 
1.1.6 G-quadruplex structure 
A guanine rich DNA or RNA sequence often forms a G-quadruplex structure. Guanine is 
different from the other nucleobases in that it self-assembles into a tetrameric structure 
called a G-tetrad. A G-tetrad is a square planar arrangement of 4 guanine nuclobases with 
each corner of the square occupied by guanine. Each guanine forms two hydrogen bonds 
(through Hoogsteen base paring) with each adjacent guanine completing the sides of the 
square. The structure of a G-tetrad is show in Figure 1.5. 
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Figure 1.5: Structure of a G-tetrad. 
 
 
Two or more of the G-tetrads stack on top of each other due to π bond stacking forming a 
G-quadruplex.69 The structures of several G-quadruplex formations are shown in Figure 
1.6. G-quadruplexes are broadly categorized into two groups based on the orientation and 
number of strands that make up the quadruplex. DNA and RNA have a 5’ end and a 3‘ 
end based in the phosphodiester bond between the nucleotides. See Figure 1.2 and 
Figure 1.3. A G-quadruplex with all four strands oriented in the same direction are called 
parallel while a G-quadruplex with at least one strand oriented in the opposite direction to 
the others is called anti-parallel.69 Figure 1.6 A and B show a parallel and an anti-parallel 
G-quadruplex respectively. In Figure 1.6A, the parallel G-quadruplex has all four strands 
are oriented in the same 5’ to 3’ orientation as denoted by the arrows; in Figure 1.6B, the 
anti-parallel G-quadruplex has two strands orientated in the 5’ to 3’ and two strands in the 
3’ to 5’ direction. However, only one strand needs to be oriented in the opposite direction 
to qualify as an anti-parallel G-quadruplex. 
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Figure 1.6: Structures of a (A) parallel unimolecular G-quadruplex, (B) anti-parallel 
unimolecular G-quadruplex. Parallel G-quadruplexes can also be (C) bimolecular and (D) 
tetramolecular. There are several additional G-quadruplex structures not shown. 
 
 
The G-quadruplexes in Figure 1.6 A and B are composed of one strand. However, they 
can also form from two (Figure 1.6 A) or four strands (Figure 1.6 B) coming together. There 
are two naming conventions to describe the molecularity of G-quadruplexes. The first 
classifies G-quadruplexes as either intramolecular, composed of a single strand, or 
intermolecular, composed of several strands. They are also classified by the number of 
strands, unimolecular, bimolecular and tetramolecular G-quadruplexes are composed of 
1, 2, and 4 strands respectively.70 
 
The quadruplex is strengthened by the addition of cations, notably K+, that coordinate 
between the tetrads. The positive cation interacts with the O6 oxygen atom of guanine 
(see Figure 1.1) stabilizing the complex.71 Both monovalent and divalent cations stabilize 
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the G-quadruplex but monovalents are usually better at stabilizing the quadruplex.72 The 
ability of monovalent cations to strengthen the G-quadruplex is K1+> Rb1+> Na1+> Cs1+>Li1+ 
and for Sr2+> Ba2+> Ca2+> Mg2+ for divalent cations.71, 72 However, the monovalent cations 
typically stabilize the G-quadruplex better than divalent cations.72 The stabilizing ability of 
the different cations is largely dependent on the ionic radius of the cation. Ions with an 
ionic radii between 1.3 and 1.5 best stabilize the G-quadruplex.71 
 
 
1.1.7 Circular dichroism (CD) spectroscopy 
Circular dichroism (CD) spectroscopy is a technique to probe the secondary structure of 
DNA and RNA.73 CD spectroscopy measure the differential absorption of left and right 
handed circularly polarized light by chiral molecules. The difference in absorption, called 
the ellipticity, is characteristic of different secondary structures. B-form or stem-loops, 
parallel G-quadrupexes, and anti-parallel G-quadruplexes can be identified from the CD 
spectrum.73-75 The CD spectra of the different secondary structures will be discussed in 
section 3.2.3. The CD signal in double stranded DNA arises from several factors including 
the electronic dipoles of the nucleobases, interactions between the bases, bond angles 
between the base and sugar, and bond angles between the sugar and the phosphate 
backbone.76, 77 CD spectroscopy can distringuish between A-, B-, Z-forms of DNA.78 For 
G-quadruplexes, the CD spectrum arrises from the interations between the G-tetrads. The 
directionality of the strands affects the conformation of the sugar-base N-glycosidic bond. 
All the bonds are in the anti conformation for parallel G-quadruplexes, but the bonds are 
in both the anti and syn conformations in anti-parallel G-quadruplexes. This causes 
different polarities of the hydrogen bonds making up the G-tetrad.79 The CD signal arises 
from the stacking between G-tetrads of the same or different polarities leading to the 
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characteristic CD spectra.80, 81 
 
 
1.1.8 Selection of aptamers - SELEX 
There are several methods to identify and isolate aptamer, but the systematic evolution of 
ligands by exponential enrichment (SELEX) process is most commonly used. SELEX is 
an iterative, combinatorial approach of exposure, isolation, and amplification. The process 
starts with a large random pool of oligonucleotides, usually 1014 to 1015 unique sequences. 
(Here we distinguish between oligonucleotides and aptamers. Oligonucleotides are short 
single stranded nucleic acid sequences that do not bind a specific target molecule; 
aptamers are single stranded nucleic acid sequences that bind a specific target molecule.) 
The oligonucleotides have a random region, usually 25 to 60 bases long flanked with 
primer regions which are 15-26 nucleotides long.82 The primer regions are used during 
amplification of the oligonucleotide pool. A schematic of the oligonucleotide is shown in 
Figure 1.7A. The random oligonucleotide pool, called a library, is synthesized chemically. 
The random pool is generated by adding all four nucleotides at once during the stepwise 
synthesis of the pool. Each nucleotide has an equal probability of reacting resulting in a 
random sequence. Some care must be taken when synthesizing the library because the 
nucleotide precursors have slightly different reaction yields.83 Random pools are easily 
synthesized by DNA synthesis companies.  
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Figure 1.7: (A) Schematic of the oligonucleotide and (B) a diagram of the SELEX cycle. 
 
 
SELEX is deceptively simple. A diagram of the process is shown in Figure 1.7. The 
oligonucleotide library is then exposed to the target molecule. Because of the large 
number of oligonucleotides, some have the right shape and properties to bind the target. 
Roughly one in 109 to 1013 oligonucleotides have sufficient affinity with higher affinity 
sequences being more rare.84 Those oligonucleotides with affinity bind the target molecule 
while the oligonucleotides with no affinity remain in solution. The bound oligonucleotides 
are then isolated from non-binders and amplified by polymerase chain reaction (PCR). 
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The amplified oligonucleotide library is again exposed to the target molecule and the cycle 
is repeated. With each cycle, the oligonucleotide library is enriched with binding 
sequences and depleted of non-binding sequences. Several cycles are needed because 
of the rarity of the high affinity oligonucleotides in the initial aptamer pool and because the 
isolation methods are not 100% efficient. Six to fifteen cycles are typically needed to 
isolate the highest affinity aptamers after which the aptamer pool is cloned and 
sequenced. 
 
 
1.1.9 Immobilization  
The immobilization of the target molecule is an essential step in the SELEX process.85 
Immobilization facilitates efficient separation of the bound from the unbound 
oligonucleotides and collection of the aptamer-target complex.85 Therefore it is important 
to select an immobilization system that has a high partition efficiency, defined as the 
percentage of the aptamer-target complex that is retained after isolation, and that 
efficiently removed the non-specific oligonucleotides. The partition efficiency and 
background removal are crucially important in reducing the number of cycles and therefore 
the time and cost of SELEX.82, 86, 87 The partition efficiency is largely determined by the 
immobilization method and background removal is achieved by thorough washing steps. 
Another concern of the immobilization method, especially with proteins, is retaining the 
tertiary structure of the target molecules. Aptamers are sensitive to changes in the 
conformation of the target molecule and immobilization methods that alter the 3D shape 
can cause failure to identify aptamers with high affinity.58  
 
There are a large number of immobilization methods and two will be highlighted here.85 
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The initial SELEX methods used affinity chromatography columns. In this system, the 
target molecule is covalently conjugated to a chromatographic medium, often a cross 
linked agarose bead. The column is equilibrated with the binding buffer and the 
oligonucleotide library exposed to the medium. The column is then washed with several 
column volumes of buffer to remove the oligonucleotides that do not bind. The aptamer is 
recovered by adding an appropriate elution buffer to the column, often deionized water, a 
high salt buffer, or a chelating agent like EDTA, which causes the aptamer to dissociate. 
The elution is then amplified by PCR and the process repeated. The second method uses 
the polyhistidine-nickel interaction to immobilize the target to the surface of magnetic 
agarose beads.88, 89 Recombinant proteins are often expressed with a polyhistidine tag to 
facilitate purification from the cell culture. The polyhistidine tag non-covalently binds to 
nickel allowing for reversible immobilization. The protein is first incubated with 
commercially available magnetic agarose beads that have a Ni2+ ion chelated onto the 
surface. Next, the oligonucleotide library is exposed to the beads and non-binding 
oligonucleotides removed by washing with buffer. The aptamer-target complex is then 
eluted using an acidic buffer or adding an excess of imidazole. The aptamer is then 
recovered from the supernatant and used in subsequent cycles. With this system, the 
aptamer-target complex is easily isolated because of the selective elution of the 
polyhistidine-Ni2+ interaction and the easy partitioning of the magnetic beads. 
 
 
1.1.10 Stringency of selection 
SELEX can be simplified into two phases. In the initial phase, the high affinity aptamers 
are an extremely small percentage of the library. It is critical that these aptamers are 
collected and passed on to subsequent rounds. Therefore incubation times are long and 
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washing steps are gentle. The selection in less stringent. In the second phase, after the 
majority of the non-binding oligonucleotides are removed, the selection conditions must 
become more stringent to isolate those aptamers with the highest affinity from those with 
mediocre affinity. If the selection stringency is not increased, only the aptamers with 
mediocre affinity will be isolated.86 This is because the library contains a large number of 
mediocre affinity aptamers and a relatively few number of high affinity aptamers. If too 
many of the mediocre affinity aptamers are retained they overwhelm the high affinity 
aptamers. The selection conditions must be such that the high affinity aptamers compete 
with and displace the more numerous mediocre affinity aptamers. The selection stringency 
is controlled by several methods like increasing salt concentration and reducing incubation 
time. But the preferred method is reduction of the target molecule concentration. By 
reducing the target concentration the aptamers with highest affinity occupy the majority of 
the binding sites while the lower affinity aptamers remain unbound and are removed during 
the isolation steps. 
 
 
1.1.11 Negative and counter selection 
It is important to amplify only those aptamer that bind the target molecule. SELEX is a 
non-discriminatory process; aptamers will be selected against any molecule in the 
system.90 In most systems there are multiple potential non-specific molecules like the 
immobilization system, carrier proteins like bovine serum albumin, and even different 
epitopes on the target molecule. These off-target aptamers complicate the identification 
of the target aptamer and can reduce the affinity of the aptamers.91 A negative selection 
round is usually performed to remove the aptamers that bind the off-target molecules. 
Negative selection is done by performing one or more SELEX cycles with the target 
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molecule absent and collecting what does not bind. Aptamers that bind off-target 
molecules are removed but the target molecule aptamers remain. A similar method called 
counter SELEX is done to isolate aptamers that bind a specific epitope, or to increase 
aptamer selectivity. Here, the oligonucleotide library is exposed to a molecule that is 
similar to the target molecule. Those aptamers that have affinity for the off-target molecule 
bind and are removed. But the aptamers that bind the target molecule, but not the off-
target molecule remain. Using this method, aptamers can be isolated that discriminate 
between molecules that differ by a methyl or hydroxyl group.2  
 
Aptamers have several characteristics that make them excellent affinity ligands like high 
affinity and selectivity for the target molecule, low cost of production, high stability, and in 
vitro selection methods. Aptamers are just now entering into commercial use in diagnostic 
assays and as therapies.92, 93 However, a significant amount of research is needed before 
aptamers are ready for use in mainstream applications. 
 
 
1.2 Fractalkine 
Fractalkine is a cell surface protein that is an exciting and unexplored target molecule for 
aptamers. Fractalkine is part of the chemokine family consisting of small proteins involved 
in the immune response and inflammation pathways.94 Fractalkine’s structure and 
physiological function make it a great target for novel therapeutics in pain management, 
inflammatory diseases such as asthma, and cancer treatments. Despite fractalkine’s 
potential, there are no such therapeutics in clinical use.95  
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1.2.1 Chemokines 
Chemokines are a family of approximately 50 structurally related proteins involved in, 
among other things, inflammation, immune response, and tumor development through the 
recruitment and regulation of leukocytes (white blood cells).94, 96-98 Chemokines are part of 
a larger family of signaling proteins called cytokines. What sets chemokines apart is the 
ability to induce chemotaxis, which is cell migration in response to a chemical gradient. 
There are four sub-classifications of chemokines, CC, CXC, XC, and CX3C, distinguished 
by four cysteine residues that form two disulfide bonds essential for structure and function, 
although this system is slowly being replaced by one based on function rather than 
structure.96, 99 Chemokines are named by their sub-family classification, for example CC, 
followed by whether it is a receptor (R) or ligand (L) status and a number designator. So 
CCL11 is ligand 11 of the CC chemokine family. 
 
 
1.2.2 Function of fractalkine 
Fractalkine (or CX3CL1), discovered in 1997 and known as neurotactin in mice, is the only 
member of the CX3C family.100, 101 Fractalkine, and its analog CXCL16, are the only 
chemokines that exist in both membrane bound and soluble forms with each form 
providing a different physiological function.102 In the membrane bound form, fractalkine 
serves primarily as an integrin independent adhesion molecule for circulating 
leukocytes.103 The unique structure of membrane bound fractalkine, shown in Figure 1.8, 
makes fractalkine an excellent adhesion molecule. Fractalkine binds to its receptor 
CX3CR1 exclusively though the chemokine domain which sits atop an extended mucin-
like stalk. The chemokine domain and mucin-like stalk are anchored to the cell membrane 
through a single pass transmembrane domain with a short cytoplasmic tail. The heavily 
  21 
glycosylated mucin-like stalk functions exclusively as a tether for the chemokine domain 
extending it though the extracellular matrix to increase accessibility to leukocytes.104 
Replacement of the mucin-like stalk with a short repeat consensus sequence of E-selectin 
of the same length as the mucin stalk showed similar binding wild type fractalkine while 
mucin alone exhibited no binding and the chemokine domain without a tether showed 
significantly reduced binding.104 Furthermore, capture of leukocytes to fractalkine occurs 
in an integrin independent manner105, 106 and under physiological shear stresses.103, 107, 108 
Membrane bound fractalkine has been found on dendritic cells,109, 110 neurons,111, 112 and 
astrocytes,113 and is believed to play an important role in cellular communication within 
the nervous system.114 
 
 
 
 
Figure 1.8: Cartoon showing the structure of membrane bound fractalkine. 
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The soluble form is a chemoattractant for natural killer cells, monocytes and subsets of T-
cells.100, 101, 115 The soluble form of fractalkine is created by cleavage of membrane bound 
fractalkine though both constitutive and induced cleavage of the mucin like stalk near the 
cell membrane creating a 95 kDa soluble protein. Constitutive shedding occurs through 
the ADAM10 metalloproteinase116, 117 while induced cleavage is done by tumor necrosis 
factor-α-converting enzyme (TACE or ADAM17).118, 119 The soluble fractalkine 
concentration in the blood is very low. The majority (85%) of healthy volunteers and 
colorectal cancer patients had undetectable soluble fractalkine levels ranging from 1.8 to 
44.8 ng/mL.120 
 
 
1.2.3 Fractalkine’s role in disease 
The role of fractalkine in disease is just beginning to be understood. It is involved in 
atherosclerosis, cardiac allograft rejection, asthma, age related macular degeneration, 
and neuropathic pain.95, 121 Much of fractalkine’s role in diseases is due to the bodies 
inflammatory response. After an injury or at the site of infection, chemokines and adhesion 
molecule recruit and direct leukocytes as part of the inflammatory response.122 Fractalkine 
takes part in this process by recruiting leukocytes through chemotaxis and by serving as 
an adhesion molecule. In the vasculature system, fractalkine is only expressed at sites of 
inflammation or injury upon stimulation by pro-inflammatory cytokines TNF-α, IFN-γ and 
IL-1β.100, 123-125 But fractalkine is involved in several other diseases. Several diseases are 
discussed in more detail below. 
 
  23 
Cancer 
Fractalkine is involved in a variety of different cancers including human gioblastoma,126 
hepatocellular carcinoma,127, 128 B16-F0 melanoma,129 neuroblastoma,130 lung cancer 
epithelium,131 epithelial ovarian cancer,132 and is implicated in the metastasis of 
prostate,133, 134 breast, pancreatic and melanoma brain cancers. The expression of 
fractalkine leads to better prognosis due to the increased recruitment of leukocytes to the 
cancer sites. Studies by Hyakudomi et al and Ohta et al on gastric adenocarcinoma and 
colorectal cancer respectively both showed better prognosis and disease free survival that 
correlated with increased fractalkine expression.135, 136 Fractalkine has also shown to 
attract natural killer cells to tumor sites resulting in a strong antitumor effect.137-139  
 
Rheumatoid arthritis 
Rheumatoid arthritis is characterized by chronic inflammation of joint tissues leading to 
leukocyte infiltration and eventually joint destruction.140 The synovium of rheumatoid 
arthritis patients show infiltration of monocytes, macrophages and CD4+ T lymphocytes 
which promote secretion of inflammatory cytokines.141 It is therefore not surprising that 
fractalkine is significantly expressed in endothelial cells, monocytes and macrophages, 
and dendritic cells while macrophages, fibroblasts and dendritic cells expressed 
CX3CR1.142, 143 Soluble fractalkine is also significantly increased in the synovial fluid of 
patients with rheumatoid arthritis compared to healthy individuals.144-146 The increased 
fractalkine concentration likely leads to chemotaxis of leukocytes.141 Fractalkine levels 
were correlated with increased joint stiffness suggesting fractalkine induced chemotaxis 
of monocytes is a factor in rheumatoid arthritis suggesting fractalkine is an important 
contributor to the disease.142 Additionally, a study in mice by Nanki et al showed that 
  24 
inhibition of fractalkine by an anti-fractalkine antibody inhibited the infiltration of 
macrophages into the synovium by 40% and reduced the symptoms of arthritis in a murine 
model.147 A fractalkine antagonist has real potential as a therapy for rheumatoid arthritis. 
 
Asthma 
Both fractalkine and its receptor, CX3CR1 play crucial roles in asthma. Asthma is 
characterized by chronic inflammation of the airway and the primary driver is the TH2 
inflammatory response.148-152 In asthmatic individuals, airway smooth muscle cells 
(ASMCs) constitutively express fractalkine.153 Immunostaining of bronchial biopsies 
showed fractalkine expression 6.5 times higher in asthmatic patients compared to controls 
with significant expression in the epithelium, submucosa, and smooth muscle cells. 
Fractalkine is upregulated in patients with asthma and rhinitis compared to healthy 
patients. Rimaniol et al. studied the fractalkine expression in 19 control and 55 patients 
with symptomatic allergic rhinitis and asthma.154 Immunohistochemistry staining of 
bronchial mucosal biopsy shows high levels of membrane bound fractalkine in endothelial 
and epithelial cells pre and post challenge. A second study also showed constitutive 
fractalkine expression in bronchoscopy and bronchial mucosal biopsies.155 The 
expression of membrane bound fractalkine in the airways of asthmatic individuals makes 
fractalkine an excellent molecule for targeted delivery of therapeutics. 
 
Atherosclerosis 
Atherosclerosis is a chronic inflammatory disease of the arterial wall. Monocytes and 
lymphocytes accumulate in the arterial lesion in response to chemokines leading to the 
migration of smooth muscle cells and the buildup of plaque.156 Several studies have shown 
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fractalkine to be a key contributor to atherosclerosis. Two studies showed polymorphic 
mutations in CX3CR1 correlated with a decreased risk of coronary artery disease.157, 158 
Studies of CX3CL1 and CX3CL1 knockout mice show dramatic reduction in lesion size.159-
162 A study in fractalkine knockout mice by Teupser et al showed up to 85% reduction in 
lesion area compared to controls.161  
 
Pain Management 
Fractalkine expressed within the nervous system, primarily on neurons, and is thought to 
function as a signaling molecule between neurons and microglia.111, 163 Intrathecal 
fractalkine induces a pain response in rats which is modulated by anti-CX3CR1 
antibody.164 Several studies implicate fractalkine as a neuron to gila signaling molecule 
inducing a pain response.165, 166 Furthermore, in CX3CR1 knockout mice showed 
significantly reduced pain response.167 Additionally, injury releases fractalkine from 
neurons. The fractalkine stimulates microglia cells leading to activation of the pain 
pathways. Addition of an anti-fractalkine antibody prevented activation of the pain pathway 
in a rat model indicating fractalkine is an important pain mediator.168  
 
Fractalkine is a good target for therapeutic applications because of its unique structure 
and function. It is involved in several diseases by recruiting and capturing leukocytes at 
sites of infection and inflammation. Currently there are no therapeutics targeting 
fractalkine.95 
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1.3 Targeted delivery 
Most injected therapeutic drugs rapidly distribute throughout the body. Large doses are 
therefore required to achieve therapeutically effective concentrations at the tumor site. As 
a result, there is significant toxicity to the healthy tissues of the body leading to many of 
the side effects common to chemotherapy. The pharmacological properties of 
conventional drugs can be improved by using drug delivery systems. Drug delivery 
systems, which include liposomes, polymeric nanoparticles, micelles, and dendrimers, are 
designed to protect an encapsulated therapeutic agent and preferentially accumulate at 
the disease site. Increased accumulation allows for a smaller drug dose, causing fewer or 
less severe side effects while maintaining or enhancing the therapeutic efficacy. 
 
Liposomes are a widely studied drug delivery system. Liposomes are self-enclosed 
vesicles composed of amphiphilic lipids, commonly phospholipids, which self-assemble 
into a bilayer morphology in aqueous solutions. Liposomes are rapidly cleared from the 
blood by the mononuclear phagocyte system (MPS), which removes foreign particles from 
the blood.169 To increase circulation time, polyethylene glycol (PEG) chains are grafted to 
the liposome surface. PEG functionalized liposomes, called stealth liposomes, reduce 
interactions through steric effects increasing circulation time. Liposomes are an excellent 
model drug delivery vehicle because they are well characterized and studied. 
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2 Development and characterization of an aptamer binding 
ligand of fractalkine using domain targeted SELEX* 
 
*Reproduced with permission from Waybrant et al.170 Copyright 2012 The Royal Society 
of Chemistry. 
 
 
 
 
2.1  Introduction 
Fractalkine, or CX3CL1, is a member of the chemokine family that bears potential for novel 
therapeutics due to its unique structure and its central role in human inflammatory 
diseases.95 Currently no therapeutics targeting fractalkine exist. Here, we developed an 
aptamer that binds with high affinity and specificity to fractalkine and can be used as a 
fractalkine antagonist or targeting ligand for the delivery of therapeutics.  
 
Fractalkine is one of two chemokines, along with CXCL16, that exist in two active forms, 
membrane bound and soluble.102 Membrane bound fractalkine captures circulating 
leukocytes through integrin independent binding with its highly specific receptor CX3CR1 
expressed on leukocytes.115, 116, 119 Fractalkine’s structure facilitates leukocyte adhesion. 
Binding occurs exclusively through the chemokine domain of fractalkine that sits atop a 
heavily glycosylated mucin-like stalk (Figure 2.1) that extends the chemokine domain 
approximately 26 nm away from the cell membrane to increase accessibility.104 The 
soluble form is produced by cleavage of membrane bound fractalkine near the cell 
membrane by the metalloproteinases ADAM10 and ADAM17 and is a potent 
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chemoattractant for natural killer cells, monocytes and subsets of T-cells.100, 116, 119 
 
 
 
 
Figure 2.1: Graphic representation of fractalkine (not to scale). The chemokine domain is 
attached to a mucin-like stalk. A single pass transmembrane domain anchors fractalkine 
to the cell. 
 
 
Drug delivery systems functionalized with a fractalkine ligand may have useful targeting 
properties because of membrane bound fractalkine’s physiological role as an adhesion 
molecule for circulating leukocytes. Fractalkine is expressed by many cancer tissues 
including human glioblastoma,126 hepatocellular carcinoma,127 neuroblastoma,130 
epithelial ovarian cancer,132 colorectal cancer,136 and gastric adenocarcinoma135 causing 
an increased leukocyte presence resulting in an antitumor effect. Furthermore, fractalkine 
has been implicated in many inflammatory diseases primarily through the recruitment and 
adhesion of leukocytes mediating the body inflammatory response.95 Anti-fractalkine 
antibodies reduce arthritic symptoms in mouse models and elimination of fractalkine from 
synovial fluid reduces angiogenesis suggesting inhibition of fractalkine may be a treatment 
for rheumatoid arthritis.141 Fractalkine also appears to play a role in allergic diseases, such 
as asthma, and local administration of a fractalkine antagonist to antigen-sensitized mice 
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resulted in reduced airway hyper-responsiveness and airway inflammation.171 
 
Other attempts to develop a fractalkine binding molecule include a peptide ligand that 
bound fractalkine but lacked sufficient affinity for cellular applications.172 Rather than a 
peptide, we developed an aptamer ligand. Aptamers, single stranded nucleic acid 
sequences that bind with high affinity and specificity, have several advantages over other 
ligands. Aptamers have long shelf lives, are easily refolded if denatured, are chemically 
synthesized allowing for precise chemical modification with little batch to batch variation, 
and show little to no immune response.6 In contrast, antibodies and proteins are large, 
often immunogenic and require animals or cell culture methods for production increasing 
cost and variability. 
 
Aptamers are identified through the systematic evolution of ligands by exponential 
enrichment (SELEX) process. SELEX is an iterative combinatorial method where the 
target molecule is exposed to 1014–1015 random nucleotide sequences. The aptamers that 
bind the target are collected and amplified by polymerase chain reaction (PCR). The target 
is again exposed to the aptamers and the process repeated for 6 to 15 cycles at which 
point the aptamer pool is cloned and sequenced. 
 
 
2.2 Results and discussion 
SELEX was performed to identify aptamer sequences with affinity for fractalkine. 
Recombinant human fractalkine containing the chemokine domain and the mucin-like stalk 
with a polyhistidine tag attached at its end was immobilized onto magnetic agarose beads. 
The polyhistidine tag binds reversibly to a Ni2+ moiety on Ni-NTA magnetic agarose beads. 
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This immobilization method is advantageous because fractalkine’s orientation is 
physiologically consistent by exposing the chemokine domain at the interface. The 
reversible polyhistidine-Ni2+ bond allows for selective elution of fractalkine–aptamer 
complex leaving behind non-specific binders.88 Immobilized fractalkine was exposed to a 
randomized library consisting of 6 × 1014 nucleotide sequences for 1 hour. The beads were 
washed three times for 5 minutes to remove non-specific binders and to select aptamers 
with slow koff kinetics.173 The aptamers with fast koff kinetics likely dissociate and are 
removed in the wash while the aptamers with slow off rates remain. 
 
We reasoned that targeting the chemokine domain would produce the desirable 
characteristics of a fractalkine aptamer. The chemokine domain extends away from the 
cell increasing accessibility and improving ligand binding. Also, an aptamer that selectively 
binds to the chemokine domain would likely block CX3CR1-fractalkine binding, whereas 
an aptamer binding other fractalkine domains, like the mucin-like stalk, may be non-
specific because other proteins have similar structures. To do this, we modified the SELEX 
protocol to exploit the lack of secondary structure in the mucin-like stalk.104 Heating to 95
°C eliminated the chemokine domain structure while leaving the mucin-like stalk 
unaffected. When the denatured fractalkine was exposed to the aptamer pool, chemokine 
domain aptamers remained in the supernatant while other aptamers bound and were 
removed. This was a simple and effective method for selecting chemokine domain 
aptamers. 
 
SELEX was stopped after twelve rounds when the PCR cycles required for aptamer pool 
amplification levelled off indicating saturation (Figure 2.2). An electrophoretic mobility shift 
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assay (EMSA) confirmed that the aptamer pool bound fractalkine (Figure 2.3). The 
aptamer was tagged with a biotin primer and was detected using a HRP-neutravidin 
chemiluminescent protocol. The aptamer bound to fractalkine (FKN) appears as a strong 
band in lane 2. Addition of an anti-histidine antibody (His Ab) that binds fractalkine resulted 
in a supershift (lane 3) due to the extra mass of the antibody. The supershift confirms the 
aptamer binds specifically to fractalkine. The aptamer did not bind the His Ab or bovine 
serum albumin (BSA) controls in lanes 4 and 5 respectively. Additionally, an anti-
chemokine domain antibody (FKN Ab) blocked aptamer binding demonstrating that the 
aptamer binds the chemokine domain (lane 6). Additional EMSA analysis is included in 
Figure 2.4. After confirming the aptamer pool bound fractalkine, the pool was cloned into 
E. coli and sequenced. Of the 85 clones sequenced, approximately 95% were the same 
sequence differing only by single nucleotide polymerase errors. The resulting aptamer, 
named FKN-S2, had the sequence 5′-
GGGGTGGGTGGGGGGCACGTGTGGGGGCGGCCAGGGTGCT-3′. 
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Figure 2.2: The number of PCR cycles needed for aptamer pool amplification per round. 
The two chemokine selection steps are denoted by 2c and 6c. The chemokine domain 
selection steps required fewer cycles because rather can collecting the beads, only the 
supernatant was amplified which contained significantly more sequences. 
 
 
 
 
Figure 2.3: EMSA analysis of the 12th SELEX round. Lane 1: aptamer with no FKN. 
Unbound aptamer band removed for brevity. See below full figure (Figure 2.4). Lane 2: 
aptamer with FKN. Lane 3: addition of the His Ab causes a supershift. Lane 4: the aptamer 
does not bind the His Ab. Lane 5: the aptamer does not bind BSA. Lane 6: an anti-
chemokine domain antibody blocks aptamer binding. All lanes have 5 nM aptamer 
concentration. 
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Figure 2.4: (A) Full image of Figure 2.3. EMSA analysis of the 12th SELEX round. Lane 
1: Aptamer with no FKN. Lane 2: Aptamer with FKN. Lane 3: Addition of the His Ab causes 
a supershift. Lane 4: The aptamer does not bind the His Ab. Lane 5: The aptamer does 
not bind BSA. Lane 6: An anti-chemokine domain antibody blocks aptamer binding. All 
lanes have 5 nM aptamer concentration. (B) Increasing concentration of SELEX aptamer 
pool binding to fractalkine (FKN) (C) Supershift assay with increasing concentrations of 
an anti-polyhistidine antibody (His Ab) showing an increased supershift corresponding to 
the His Ab-fractalkine aptamer complex. The aptamer concentration was 5 nM with 1 pmol 
of FKN used in each lane. 
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The dissociation constant of FKN-S2 for fractalkine was determined using a radioactive 
homologous competition filter binding assay. Dilutions of unlabeled FKN-S2 aptamer were 
mixed with a constant concentration of 32P ATP labeled FKN-S2. The dilutions were then 
incubated with 25 pM fractalkine for 1 hour at room temperature. The fractalkine 
concentration was iteratively decreased until it was approximately 100 times lower than 
the dissociation constant to prevent radioligand depletion effects. Bound aptamer was 
collected by filtration through a nitrocellulose membrane and the dissociation constant 
determined by non-linear regression analysis. The dissociation constant was determined 
to be 3.4 ± 0.7 nM based on the binding curve shown in Figure 2.5. 
 
 
 
 
Figure 2.5: Homologous competition curve for FKN-S2. Labeled and unlabeled aptamer 
were incubated with 25 pM of fractalkine for 1 hour. Bound aptamer was collected by 
filtering through a nitrocellulose membrane. Results show the mean ± standard error from 
9 independent experiments (n = 9) with each experiment performed in quadruplicate. 
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EMSA analysis of the aptamer pool demonstrated the aptamer bound the chemokine 
domain of fractalkine. However, the synthesized aptamer was significantly different from 
the aptamer pool due to the removal of the flanking primer sequences and because the 
aptamer pool contained several sequences. To ensure the aptamer was specific to 
fractalkine, an anti-fractalkine chemokine domain antibody (FKN Ab) was used to block 
aptamer binding to fractalkine. Three aptamer concentrations, with a constant labeled to 
unlabeled ratio, were incubated with fractalkine and fractalkine plus the antibody (Figure 
2.6). Bound aptamer was collected on a nitrocellulose membrane. There was significant 
aptamer binding at all concentrations and the addition of the anti-chemokine domain 
antibody reduced binding to background levels. This demonstrates that the FKN-S2 
aptamer binds directly to the chemokine domain as observed in the EMSA analysis. A 
similar experiment was done with a scrambled version of FKN-S2 and no binding was 
observed (Figure 2.7). 
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Figure 2.6: Anti-fractalkine antibody blocks binding of the FKN-S2 aptamer to fractalkine. 
100 nM of antibody (FKN Ab) that is specific for the chemokine domain of fractalkine was 
allowed to bind for 30 minutes prior to aptamer addition. Results show the mean ± 
standard error from 4 independent experiments (n = 4). Two tailed t-test with unequal 
variances was used to determine significance, *p < 0.005, **p < 0.001. 
 
 
 
 
Figure 2.7: Anti-fractalkine antibody blocking of binding of the scrambled FKN-S2 aptamer 
to fractalkine. No binding was seen for the scrambled aptamer. 100 nM of antibody that is 
specific for the chemokine domain of fractalkine (FKN Ab) was allowed to bind for 30 
minutes prior to aptamer addition. Results show the mean ± standard error from 4 
independent experiments (n=4). Two tailed t-test with unequal variances was used to 
determine significance, † p > 0.01. 
 
 
  37 
To further show specificity, FKN-S2 binding was tested against fractalkine, heat-denatured 
fractalkine and chemokines CCL8 and CXCL16. The results are shown in Figure 2.8. FKN-
S2 binding to heat-denatured fractalkine was significantly reduced compared to native 
fractalkine while no binding was observed to either chemokines. 
 
 
 
 
Figure 2.8: FKN-S2 binding to fractalkine, heat-denatured fractalkine, chemokine CCL8 
and chemokine CXCL16. The aptamer and the protein (0.2 nM) were incubated for 1 hour 
at room temperature. Results show the mean ± standard error from five independent 
experiments (n = 5). 
 
 
FKN-S2 contains 40 nucleotides and we investigated if truncation of the aptamer would 
result in sequences with similar affinity to fractalkine but with fewer nucleotides. Three 
truncated versions of the FKN-S2 aptamer were synthesized with five nucleotides 
removed from the 5′ end (FKN-S2a), five from the 3′ end (FKN-S2b) and five from each 
end (FKN-S2c). Additionally, a random 40-mer (5′-
CTATCGGCGACATGAACTTTGGCAAGGGCATCTGGTCCAT-3′) was used as a control. 
The relative affinities of the truncated aptamers were tested using a heterogeneous 
competition assay with radiolabeled full length FKN-S2 (Figure 2.9). IC50 values (the 
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concentration of 50% reduction in binding) were determined by non-linear regression 
fitting of the data to the binding equation given in the methods section and the values are 
shown in Table 2.1.  
 
 
 
 
Figure 2.9: Competitive binding curves of truncated FKN-S2. Open square ( ) FKN-S2; 
filled diamond (♦) FKN-S2a; open triangle (Δ) FKN-S2b; filled triangle (▲) FKN-S2c; open 
circle (○) random aptamer. Results show the mean ± standard error from 7 independent 
experiments (n = 7) with each experiment performed in duplicate. 
 
 
 
Table 2.1: IC50 values of the truncated aptamers. 
 FKN-S2 FKN-S2a FKN-S2b FKN-S2c Random 
IC50 (nM) 9.5 72 200 5410 >100 000 >100 000 
 
 
 
Interestingly, removal of 5 nucleotides from the 5′ end (FKN-S2a) resulted in near 
complete loss of binding with an IC50 value of 72 200 nM. This suggests the 5′ end of the 
FKN-S2 aptamer is essential for binding. Removal from the 3′ end (FKN-S2b) similarly 
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gave a decrease although less drastic with an IC50 of 5410 nM. Sequence FKN-S2c and 
the random aptamer showed no binding both with IC50 values greater than 100 μM. The 
large reduction in affinity after removal of 5–10 nucleotides from the FKN-S2 sequence 
suggests the flanking nucleotides either participate directly in binding or are essential for 
stabilizing the aptamer structure. The ends may directly interact with fractalkine or may 
create the aptamer structure necessary for binding. Internal truncations were not 
investigated after observing the drastic reduction in affinity from end truncation. 
 
We developed an aptamer via SELEX that binds with high affinity to fractalkine with a 
dissociation constant of 3.4 ± 0.7 nM. The aptamer was shown to be specific for the 
chemokine domain of fractalkine and truncation of the aptamer significantly reducing 
binding. This aptamer has many potential uses including as a therapeutic agent itself, as 
part of a targeted drug delivery system or as an investigative tool to manipulate fractalkine-
CX3CR1 binding which has shown important in different diseases such as cancer, asthma 
and rheumatoid arthritis. 
 
 
2.3 Materials and methods 
 
2.3.1 Materials 
Recombinant human fractalkine containing the chemokine domain, mucin-like stalk and 
a poly-histidine tag (FKN; Catalog Number 365-FR-025) and an anti-fractalkine chemokine 
domain antibody (FKN Ab; Catalog Number AF365) were obtained from R&D Systems 
(Minneapolis, MN). The anti-polyhistidine tag antibody was obtained from Millipore (His 
Ab; Billerica, MA, Catalog Number AB3517). The aptamer library and all primers were 
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obtained through Integrated DNA Technology, Inc. (Coralville, IA, USA). Ni-NTA Magnetic 
Agarose Beads (Catalog Number 36111) and Streptavidin MagneSphere Paramagnetic 
Particles (Catalog Number Z5481) were obtained from Qiagen (Valencia, CA) and 
Promega (Madison, WI) respectively. All PCR reagents, Hot-Start Taq DNA Polymerase 
(Catalog Number CB4040-1), 10x PCR buffer (Catalog Number CB3702-7) and dNTP 
master mix (Catalog Number CB4421- 4) were obtained from Denville Scientific (South 
Plainfield, NJ). The TOPO-TA cloning kit with one-shot chemically competent TOP10 E. 
coli cells (Product Number K4500-01) was obtained from Invitrogen (Carlsbad, CA). 
Chemokines CCL8 and CXCL16 were obtained from PeptroTech (Rocky Hill, NJ). 
 
 
2.3.2 Selection of aptamers against fractalkine 
The aptamer library, consisting of a 40-mer random region with flanking forward and 
reverse priming regions, WP-18 and WP-20 respectively, are shown below. Primer WP-
20 contains a biotin tag on the 5’ end to facilitate strand separation. 
 
Aptamer Library: 5’-GTGCAGTCAAAGACGTCC-N40-GACCATGAAGTGCGATTGCC-3’ 
Primer WP-18: 5’-GTGCAGTCAAAGACGTCC - 3’ 
Primer Biotin WP-20: Biotin-5'-GGCAATCGCACTTCATGGTC -3’ 
 
The fractalkine was immobilized through a polyhistidine-Ni2+ interaction. Approximately 50 
μL of Ni-NTA magnetic agarose beads were combined with 1 µg of fractalkine and 
incubating for 1 hour at room temperature on a rotisserie shaker. The beads were washed 
three times to remove un-immobilized fractalkine. 
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For the initial round of SELEX, 50 pmol of fractalkine was incubated with 500 pmol of 
aptamer library for 120 minutes on a rotisserie shaker at room temperature in selection 
buffer (phosphate buffered saline (PBS) with 10 mM imidazole and 0.005% (v/v) Tween-
20, pH 7.4). The aptamer library was heat denatured and snap cooled in ice water to 
eliminate hybridization. Following incubation, the beads were quickly washed three times 
with selection buffer followed by three 5 minute washes. The aptamer-fractalkine complex 
was eluted by 2 additions of 50 μL of 250 mM imidazole in PBS. The aptamer pool was 
amplified using polymerase chain reaction (PCR) using 1 μM of primers WP-18 and WP-
20, 800 μM total dNTP and 1.25 units of Taq per 50 μL reaction. Touchdown PCR was 
used to amplify the aptamer pool according to the following program: 5 minutes at 95°C, 
10 cycles of 5 minutes at 95°C, 15 sec at 94°C, 15 sec at 72°C*, and 15 sec at 72°C with 
the * temperature decreased by 1°C per cycle, followed by 15 sec at 94°C, 15 sec at 62°C, 
and 15 sec at 72°C with an extension step of 1 minute at 72°C. The number of cycles used 
was adjusted depending on the SELEX round to prevent byproduct formation. The anti-
sense strand was removed by denaturing the aptamer at 95°C for 5 minutes followed by 
snap cooling in ice water and incubation for 5 minutes on ice with Streptavidin 
MagneSphere Paramagnetic Particles. In subsequent rounds, the aptamer pool was 
reduced from 500 to 100 pmol while the fractalkine was reduced from 6 pmol to 1 pmol 
depending on the round to increase the stringency of selection. All binding occurred for 30 
minutes at room temperature in selection buffer. SELEX was stopped after the 12th round 
when the PCR cycles needed for amplification of the aptamer leveled off between rounds 
10 to 12 (Figure 2.2).  
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2.3.3 Domain targeted SELEX: Chemokine domain selection steps 
Selection of chemokine domain aptamers was performed after rounds 2 and 5. Fractalkine 
was denatured by heating to 95°C for 10 minutes followed by snap cooling. The fractalkine 
was bound to Ni-NTA beads for 1 hour. The aptamer was added and incubated in selection 
buffer for 60 and 30 minutes at room temperature for counter selections following rounds 
2 and 6 respectively. Unbound aptamer was collected and amplified by PCR. 
 
 
2.3.4 EMSA analysis of aptamer pool 
An electrophoretic mobility shift assay (EMSA) demonstrated binding of the aptamer pool 
to fractalkine. Asymmetric PCR was used to create biotinylated aptamer with the following 
reagent concentrations: DNA Polymerase (1.25 units per 50 μL reaction), 10x PCR buffer, 
dNTP (total dNTP concentration of 500 μM), Biotin-WP-18 (1 μM), WP-20 (0.01 μM), water 
(added to 50 μL) and SELEX round 12 aptamer template (0.1 pmol). 
 
Varying concentrations of 5’ biotinylated round 12 aptamer pool was incubated with 1 pmol 
of fractalkine for 30 minutes at room temperature in selection buffer. A similar procedure 
was used for the supershift assay. An anti-polyhistidine tag antibody, fractalkine and 
aptamer were incubated for 30 minutes at room temperature. For the chemokine blocking 
experiment, 15 pmol of anti-chemokine antibody was pre-incubated with fractalkine for 15 
minutes prior to aptamer addition. After binding, the samples were run at 80V on a non-
denaturing 6% polyacrylamide gel in 0.5x TBE buffer (45 mM Tris-Base, 45 mM Boric 
Acid, 1 mM EDTA). The samples were transferred to a nylon membrane (Pall Biodyne B) 
at 380 mA for 30 minutes and crosslinked by UV exposure. The membrane was developed 
using a LightShift Chemiluminescent EMSA Kit (Thermo Scientific; Product Number 
  43 
20148) according to manufacturer’s instructions.  
 
Figure 2.3 from the main text is recreated in Figure 2.4-A to show the entire gel which 
shortened for space considerations. An electrophoretic mobility shift assay confirmed that 
the aptamer pool bound fractalkine in a dose dependent manner (Figure 2.4-B). In Figure 
2.4-C an increasing concentration of an anti-polyhistidine tag antibody (His Ab) bound the 
polyhistidine tag of the recombinant fractalkine causing a supershift of the fractalkine-
aptamer band. Increasing antibody concentrations intensified the supershift while 
decreasing the fractalkine aptamer band. No binding was observed in the His Ab control 
well indicating the aptamer does not bind the antibody. 
 
 
2.3.5 Cloning and sequencing of aptamer pool 
The aptamer pool was cloned into a TA vector (Invitrogen pCR2.1 Topo TA cloning kit) 
and heat shocked into chemically competent E. coli (One Shot TOP10 Chemically 
Competent E. coli; Invitrogen) according to the manufacturer’s instructions. The 
transformed E. coli were plated onto LB agar plates with 50 μg/ml kanamycin and 40 
mg/mL of X-gal and successfully transformed colonies were selected through blue/white 
screening. The sequencing region was amplified by colony PCR and amplicon size verified 
by agarose gel electrophoresis. ExoSAP-IT (Affymetrix, Inc.; Product Number 78201) was 
used to remove the excess primers. The clones were sequenced of the M13 Forward 
primer on an ABI 3730xl using ABI BigDye version 3.1 terminator chemistry by the 
University of Minnesota BioMedical Genomic Center sequencing facility. Aptamer 
candidates were aligned using MEGA 5 software. 
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2.3.6 FKN-S2 aptamer homologous competitive binding assay 
FKN-S2 was labeled with γ-32P ATP using a T4 polynucleotide kinase (PNK) (Roche 
Applied Science) according to the manufacturer’s instructions. Briefly, 10 units of PNK 
were added to 25 pmol of aptamer in the supplied PNK buffer. The reaction proceeded for 
45 minutes at 37°C and was stopped by the addition of 10 µL of a 0.5 M EDTA solution. 
Unincorporated γ-32P ATP was removed using a Sephadex G-50 spin column. 
 
The aptamer dissociation constant was measured using a homologous competitive 
binding assay. The aptamer concentration was quantified by UV absorbance measured 
using a Thermoscientific Nanodrop spectrophotometer and an extinction coefficient 
obtained from Integrated DNA Technology, Inc based on sequence composition. 
 
All binding experiments occurred in binding buffer composed of PBS with 0.5 μg/mL poly 
dA:dT and 50 μg/mL bovine serum albumin (BSA), pH 7.4. Unlabeled full length FKN-S2 
aptamer was diluted in binding buffer and a constant concentration of radiolabeled full 
length FKN-S2 aptamer added to each dilution. Full length fractalkine or an equivalent 
concentration of BSA was diluted in binding buffer to 50 pM. Aptamer and fractalkine/BSA 
was incubated for 1 hour at room temperature. Following incubation, samples were filtered 
through a nitrocellulose membrane using a bio-rad dot blot apparatus. Each well was 
washed 3 times with 200 μL of PBS to remove unbound aptamer. The membrane was 
dried and exposed to a storage phosphor screen overnight and imaged (Packard 
Cyclone). Binding was quantified using ImageJ and the Dot Blot Analyzer plug-in. The 
data was fit to the following equation 𝐴𝐵 = 𝐴𝐵𝑀𝐴𝑋 (
[𝐴]
[𝐴]+[𝑋]+𝐾𝑑
) − 𝑏 where AB is the 
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measured signal, ABMax is the maximum signal, [X] is the concentration of unlabeled 
competitor, [A] is the hot aptamer concentration, b is the background binding, and Kd is 
the dissociation constant. Data was fit using non-linear regression analysis with the 
program Origin 8. 
 
 
2.3.7 Truncated FKN-S2 aptamer competitive binding assay 
Unlabeled aptamer was serially diluted from 10,000 nM to 0.1 nM in binding buffer (PBS 
with 0.1 μg/mL Poly (dA:dT) and 50 μg/mL BSA, pH 7.4). 1 nM of unlabeled FKN-S2 and 
5,000 cpm/μL (counts per minute/μL) of radio-labeled full length FKN-S2 were heat 
denatured and snap cooled before addition to either fractalkine or a BSA control at a 
concentration of 0.1 nM and incubated for 1 hour at room temperature. The solutions were 
filtered through a nitrocellulose membrane and exposed to a storage phosphor film 
overnight and imaged. The binding was quantified using ImageJ and the Dot Blot Analyzer 
plug-in. Data was fit using the non-linear regression program Origin 8 to the equation 𝐴𝐵 =
𝐴𝐵𝑀𝐴𝑋 (1 −
[𝑋]
[𝑋]+𝐼𝐶50
) where AB is the measured signal, ABMax is the maximum signal, [X] 
is the concentration of unlabeled competitor and IC50 is the competitor concentration at 
which the signal is reduced by 50%. 
 
 
2.3.8 Anti-fractalkine antibody blocking assay 
Unlabeled FKN-S2 and scrambled FKN-S2 aptamer (sequence 5’-
GTTGGGATGAGGGTGGGCGGGCGCGGCGGCTGGGGGTCGG-3’) were diluted to 10 
nM in binding buffer (PBS with 50 μg/mL BSA and 2.5 μg/mL Poly (dA:dT); pH 7.4). 
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Approximately 75,000 cpm/well of radio-labeled aptamer was added and the samples 
were diluted to 5 and 1 nM. Each dilution was heat denatured and snap cooled. Full length 
fractalkine was diluted to 0.25 nM and approximately 100 nM of anti-chemokine domain 
antibody (FKN Ab) was added and allowed to bind for 30 minutes at room temperature. 
The aptamer was added to the protein solution and incubated at room temperature for 30 
minutes. Bound aptamer was collected by filtering the samples thorough at nitrocellulose 
membrane and signal captured with a phosphor film and imaged. The background binding 
signal was removed from the FKN and FKN Ab + FKN samples by subtracting the signal 
from a well containing an identical concentration of BSA without FKN or FKN Ab. Binding 
was quantified using ImageJ. Results for the scrambled FKNS2 aptamer are shown in 
Figure 2.7. 
 
 
2.3.9 FKN-S2 binding to heat-denatured fractalkine and chemokines CCL8 and 
CXCL16 
A saturation binding experiment was performed examining the binding of FKN-S2 to heat-
denatured fractalkine and chemokines CCL8 and CXCL16. CCL8 represents the CC 
family of chemokines while CXCL16 was chosen because it is structurally similar to 
fractalkine. CXCL16 contains a chemokine domain atop a mucin like stock which is 
anchored to the cell with a transmembrane domain. The membrane bound protein is 
cleaved to produce a soluble version of the protein. Membrane bound CXCL16 can also 
act as an adhesion molecule to certain T cell types. These similarities to fractalkine made 
it an excellent candidate to test FKN-S2 binding. 
 
FKN-S2 was labeled with γ-32P ATP using a T4 polynucleotide kinase as described in the 
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FKN-S2 Aptamer Homologous Competitive Binding Assay section. Unlabeled FKN-S2 
aptamer and 106 counts per minute of radiolabeled FKN-S2 aptamer were mixed in 
binding buffer (PBS with 50 μg/mL BSA and 2.5 μg/mL Poly (dA:dT); pH 7.4) and the 
aptamer was denatured at 95°C for 5 minutes followed by snap cooling in ice water for 5 
minutes. The aptamer was then serial diluted in binding buffer and the dilutions added to 
full length fractalkine, heat-denatured fractalkine and chemokines CCL8 (PeproTech 
Catalog Number 300-15) and CXCL16 (PeproTech Catalog Number 300-55). All proteins 
were at a concentration of 0.2 nM. Fractalkine was denatured by heating to 95°C for 10 
minutes followed by incubation on ice until use. The aptamer and protein were incubated 
for 1 hour at room temperature. Bound aptamer was collected by filtering the samples 
thorough at nitrocellulose membrane and signal captured with a phosphor film and 
imaged. The background was measured from wells containing an identical concentration 
of BSA without the protein. Binding was quantified using ImageJ. Results are shown in 
Figure 2.8. FKN-S2 did not bind to the chemokines CCL8 or CXCL16, however, some 
binding was seen to heat-denatured fractalkine. Heat-denaturing reduced binding by 2.5 
fold at saturation. The binding that was seen may be due to incomplete denaturing or 
refolding of fractalkine during the experiment. 
 
 
  
  48 
3 The effect of polyethylene glycol, alkyl, and oligonucleotide 
spacers on the binding, secondary structure and self-
assembly of fractalkine binding FKN-S2 aptamer-amphiphiles 
 
 
 
 
 
3.1 Introduction 
The ability of antibodies to selectively bind a molecular target sparked a revolution in 
biotechnology leading to the creation of novel diagnostics, therapeutics, and imaging 
techniques.3 Aptamers are short strands of nucleic acids that, like antibodies, bind 
molecular targets with high affinity and specificity. Positive characteristics of aptamers 
include in vitro selection, synthetic synthesis, reproducible and specific chemical 
modifications, and good chemical and thermal stability.1, 7 Because of these advantages, 
aptamers are used for sensors and diagnostics,9, 10 affinity separations,11 and drug delivery 
and imaging applications.6, 12, 15, 174  
 
Aptamers are often modified to reduce nuclease digestion,12, 56 increase circulation 
lifetime,175 increase association with cellular membranes,176 induce micelle formation,177 
or functionalize liposomes.178, 179 Commonly a polyethylene glycol (PEG) or an oligo-T 
(thymine) spacer is added to the aptamer, especially when attaching the aptamer to a 
surface.180, 181 However, these modifications can affect the affinity of the aptamer for the 
target molecule through steric repulsion or alteration of the aptamer secondary structure.  
 
Amphiphiles often form supramolecular structures.182 Previous studies have shown that 
aptamer-amphiphiles can form micelles, which can be used for drug delivery or bottom up 
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assembly.14, 183 Nucleic acid amphiphiles with a single nucleoside as the headgroup and 
a 12 carbon dialkyl tail self-assembled into cylindrical micelles and helical ribbons.184 
However, the single nucleoside headgroup lacked ligand-receptor binding capabilities. 
Recent work by our group has shown that aptamer-amphiphiles with a 25 nucleic acid 
aptamer headgroup (that binds to Muc-1 glycoprotein) and C16 dialkyl tails (similar to the 
ones used in this study) self-assembled into micelles when the amphiphile did not contain 
a spacer (NoSPR) or when a hydrophilic PEG4 or PEG8 spacers were used, but self-
assembled into micelles and nanotapes, flat or twisted, when the hydrophobic C12 or C24 
spacers were used.185 The nanotapes, the presence of which could not be predicted by 
the standard packing parameter analysis, were bilayer structures with the hydrocarbon 
tails and spacers forming the hydrophobic core and the aptamer headgroups extending 
away from the hydrophobic interfaces.185 We hypothesized that the hydrophobic tails and 
poly-carbon spacers, through attractive hydrophobic interactions, forced the aptamer 
headgroups together reducing the interfacial headgroup area and thereby allowing 
nanotape formation. 
 
Previously, we developed the FKN-S2 aptamer that binds to the cell surface protein 
fractalkine (CX3CL1) with a dissociation constant (Kd) of 3.4 ± 0.7 nM.170 Fractalkine is a 
chemokine involved in inflammation pathways through the recruitment and adhesion of 
leukocytes95, 171, 186 and is expressed on inflamed endothelial cells and certain cancers.126, 
127, 132, 135 In this work we investigated the effects of the tail and spacer on the affinity, 
secondary structure and self-assembly of FKN-S2 amphiphiles. The 40-mer FKN-S2 
aptamer (sequence shown in Figure 3.1A) was synthesized with a 6 carbon (C6) amino 
linker added to either the 5’ or 3’ end of the aptamer. Tails with different spacers (a subset 
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of which are shown in Figure 3.1B) were then conjugated to the C6 linker creating the 
aptamer-amphiphile (Figure 3.1C). The effect of the tail and different spacers on the 
aptamer-amphiphile binding affinity for fractalkine was measured using a competition 
binding assay. The aptamer and aptamer-amphiphile secondary structure were probed 
with circular dichroism (CD) spectroscopy and thermal melting analysis to investigate the 
effect of the tail on secondary structure. Cryogenic transmission electron microscopy 
(cryo-TEM) was used to visualize the self-assembled structures of the FKN-S2 aptamer-
amphiphiles and a 40-mer oligonucleotide with a similar secondary structure. Finally, 
considering that the FKN-S2 aptamer can be used to functionalize nanoparticles targeted 
to fractalkine expressing cells, liposomes were functionalized with a FKN-S2 amphiphile 
and targeted to fractalkine expressing cells as a targeted drug delivery proof of concept. 
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Figure 3.1: (A) The sequence of the FKN-S2 aptamer with the 3’ C6 linker, (B) structures 
of the tail, a saturated dialkyl C16 lipid like molecule, with a subset of the different spacers: 
NoSPR (no spacer was used), PEG8, C24 and T10, and (C) structure of the aptamer-
amphiphile with a C12 spacer. The aptamer was purchased with a six carbon amino linker 
(C6 Linker) on either the 5’ or 3’ end to which the tail was conjugated. 
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3.2 Materials and methods 
 
3.2.1 Materials 
All aptamers were synthesized by Integrated DNA Technologies (Coralville, IA, USA). Full 
length fractalkine (Product No. AF365) was purchased from R&D Systems (Minneapolis, 
MN). Whatman Protran nitrocellulose membrane (Product No. NBA085A) was used for 
the radioactive competition binding assays. The PEG spacer precursors CA(PEG)4 
(Product No. 26120), CA(PEG)8 (Product No. 26122), and CA(PEG)24 (Product No. 26125) 
were purchased from Thermo Fischer Scientific (Rockford, IL, USA). The alkyl spacers 
were synthesized from 12-aminododecanoic acid obtained from Sigma-Aldrich (St. Louis, 
MO, USA). The γ-32P adenosine triphosphate (ATP) was purchased from PerkinElmer 
(Waltham, MA, USA) and the T4 polynucleotide kinase was purchased from Roche 
Applied Science (Indianapolis, IN, USA). All other solvents and reagents were purchased 
from Sigma Aldrich. The phosphate buffered saline (PBS) buffer was composed of 136.9 
mM sodium chloride, 2.68 mM potassium chloride, 8.1 mM sodium hydrogen phosphate, 
and 1.76 mM potassium dihydrogen phosphate. 
 
 
3.2.2 Synthesis of spacer-tails 
The tails were synthesized as described previously.187 Briefly, two cetyl alcohols were 
conjugated to the carboxyl groups of a L-glutamic acid through ester linkages. A succinic 
acid linker was reacted to the glutamic acid amino group by an amide bond. 
 
The heterobifunctional carboxy-amine spacers PEG4, PEG8, PEG24, and C12 were 
purchased from suppliers. The oligonucleotide spacers were added during aptamer 
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synthesis. The spacers were added to the carboxyl group of the succinic acid linker using 
the N-hydroxysuccinimide (NHS) chemistry as described previously.185 Briefly, the tails 
were dissolved in ethyl acetate and N,N-dicyclocarbodiimide (DCC, 2x molar excess) and 
NHS (2x molar excess) were added and reacted overnight at 50 °C. The insoluble 
byproduct dicyclohexylurea was removed by filtration. The NHS-tails were precipitated 
twice in ethyl acetate and the product molecular weight verified using mass spectrometry. 
The NHS-tails were then reacted with excess spacer in dichloromethane for 24 hr at 50 
°C. The primary amine of the heterobifunctional spacer reacted with the NHS ester of the 
tails forming an amide bond. The spacer tails were stored at -20 °C. The C24 tails were 
made by reacting C12-tails with 12-aminododecanoic acid using the same procedure. 
 
 
3.2.3 Aptamer quantification 
All aptamer and aptamer-amphiphile concentrations were measured by absorbance at 260 
nm. The aptamer was diluted to approximately 2.5-5.0 μM in TE buffer (10 mM Tris Base, 
1 mM EDTA, pH 8.0) and the absorbance measured at 260 nm using either a Thermo 
Scientific Nanodrop instrument or a BioTek Synergy H1 microplate reader equipped with 
a take3 plate. The aptamer extinction coefficients were found using the Integrated DNA 
Technology OligoAnalyzer 3.1 software. 
 
 
3.2.4 Synthesis of aptamer-amphiphiles 
The FKN-S2 aptamer was purchased from Integrated DNA Technology with an amino-C6 
linker attached to either the 3’ or 5’ end of the aptamer. The FKN-S2 sequence is 5’-
GGGGTGGGTGGGGGGCACGTGTGGGGGCGGCCAGGGTGCT-C6 linker-3’ A 1.5x 
  54 
molar excess of cetyltrimethylammonium bromide (CTAB) (excess based on the number 
of phosphates on the aptamer backbone) was added to the aptamer forming a CTAB-
aptamer precipitate. The precipitate was collected and dried under vacuum. The CTAB-
aptamer was dissolved in 1:9 volume mixture of dimethyl sulfoxide (DMSO) and N,N-
dimethylformamide (DMF) and heated to 80 °C to dissolve the CTAB-aptamer. A 5x 
excess of NHS-tails was added and reacted at 65 °C for 24 hr. Fresh tails were added and 
reacted for an additional 12 hr. The DMSO and DMF was removed by evaporation. The 
CTAB-aptamer was dissolved in 825 μL of ethanol. 30 μL of 3 M sodium acetate and 300 
μL of water were added to displace the CTAB and precipitate the aptamer. The precipitate 
was collected, dissolved in 300 μL of water and precipitated with sodium acetate and 
ethanol. The aptamer was purified by reverse phase HPLC on an Agilent Zorbax C-18 
reverse phase column (4.6 x 150 mm). The mobile phase buffers were 10% methanol and 
90% water (v/v) (Buffer A) and 100% methanol (Buffer B). Both buffers contained 100 mM 
hexafluoro-2-propanol and 14.5 mM triethylamine. The sample was separated using a 
linear gradient from 100% Buffer A to 100% Buffer B over 20 min at 1 mL/min. The 
aptamer-amphiphile peak was collected, dried, and precipitated twice with sodium acetate 
and ethanol. The molecular weight was verified by LC-MS. The final product was dissolved 
in TE buffer and stored at -20 °C. 
 
 
3.2.5 Radioactive competition binding assay 
FKN-S2 aptamer was radiolabeled with γ-32P ATP using a T4 polynucleotide kinase 
(PNK) (Roche Applied Science; Penzberg, Germany) as described previously.170 Varying 
concentrations of the aptamer-amphiphile were mixed with approximately 50,000 counts 
per min (CPM) of radiolabeled FKN-S2, and 1 nM unlabeled FKN-S2 in binding buffer 
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(PBS with 50 μg/mL bovine serum albumin (BSA) and 0.1 μg/mL of poly(dA:dT), pH = 
7.4). The aptamer mixture was heated to 90-95 °C in a water bath for 5 min and snap 
cooled in ice water to reform the aptamer into a binding conformation. The aptamer mixture 
was then added to fractalkine (0.1 nM final concentration) that was free in solution and 
incubated at room temperature for 1 hr in a 96 well plate. Following incubation, the 
fractalkine-aptamer solution was filtered through a nitrocellulose membrane using a dot 
blot vacuum apparatus. The membrane was washed three times with PBS to remove 
unbound aptamer, dried, and the radioactivity measured using phosphor screen (Packard 
Cyclone; Downers Grove, IL). Binding was quantified using ImageJ and the Dot Blot 
Analyzer plug-in. Non-linear regression was used to fit the data to the equation 𝑅𝑎𝑑𝐴𝑐𝑡 =
𝑅𝑎𝑑𝐴𝑐𝑡𝑀𝑎𝑥 (1 −
[𝑋]
[𝑋]+𝐼𝐶50
) where RadAct is the measured radioactivity, RadActMax is the 
radioactivity at zero competitor concentration, [X] is the competitor concentration, and IC50 
is the competitor concentration that results in a 50% radioactivity reduction. Statistical 
significance was determined using a two tailed Student’s t-test with unequal variances. 
 
 
3.2.6 Measurement of critical micelle concentration 
The critical micelle concentration (CMC) was measured using Nile red fluorescence.188, 189 
A stock solution of 1 mg/mL of Nile red (Sigma-Aldrich; microscopy grade) dissolved in 
acetone was diluted to 0.04 mg/mL in deionized (DI) water. 50 μL of the diluted dye was 
added to 50 μL of varying concentrations of aptamer-amphiphile in DI water (from 0 to 
2000 nM final concentration) for 1 hr at room temperature. The fluorescent intensity was 
measured using a BioTek Synergy H1 microplate reader at an emission/excitation of 
540/635 nm.  
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3.2.7 Circular dichroism spectroscopy 
All CD spectroscopy spectra were measured using a Jasco J-815 CD spectrophotometer 
(Biophysical Spectroscopy Center at the University of Minnesota). The aptamer was 
precipitated using sodium acetate and ethanol and washed with 70% ethanol to remove 
residual salts. The aptamer was dissolved in DI water, 20 mM potassium chloride, or PBS 
buffer. The aptamer was heated in a 95 °C heating block for 5 min and rapidly cooled to 
room temperature prior to measurement. All spectra were taken within 1 hr. The CD 
spectrum was measured at 22 °C in a 1.0 cm quartz cuvette and the background buffer 
signal was subtracted.  
 
 
3.2.8 Circular dichroism melting curves 
The aptamer was dissolved in PBS and degassed under vacuum for 10 min. The sample 
was sealed in a quartz cuvette using a glass cover slip and silicone sealant to prevent 
evaporation. The melting curves were measured using a Jasco J-815 CD 
spectrophotometer (Biophysical Spectroscopy Center at the University of Minnesota) with 
a 6 cell Peltier heater. The samples were held at 95 °C for 10 min to fully denature the 
aptamer and then cooled from 95 °C to 25 °C and heated from 25 °C to 95 °C at 0.25 
°C/min. No hysteresis was seen using this temperature gradient. The sample temperature 
was monitored using a thermocouple inserted into a buffer filled cuvette. CD absorption 
was measured every 1 °C at 265 and 285 nm. The melting temperature and 
thermodynamic parameters were determined assuming a two state model as described 
elsewhere.190 
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3.2.9 Cryogenic transmission electron microscopy  
4.5 μL of 100-500 µM amphiphile samples were deposited onto lacey formvar/carbon 
copper grids that were treated for 30 sec with glow discharge to make the grids more 
hydrophilic. The samples were then vitrified in liquid ethane using a Vitrobot cryo-plunger 
(Vitrobot parameters: 5 sec blot time, -1 offset, 3 sec wait time, 3 sec relax time, 95 % 
humidity). Following vitrification, grids was transferred to a Tecnai G2 Spirit TWIN 20-120 
kV / LaB6 Transmission Electron Microscope and imaged at using an accelerating voltage 
of 120 kV and an Eagle 2k CCD camera. 
 
 
3.2.10 Aptamer functionalized liposome binding to MCA-38.FKN cells 
The liposomes were prepared by the thin film hydration and extrusion method described 
elsewhere.191 Dipalmitoylphosphatidylcholine (DPPC), cholesterol, and 
dipalmitoylphosphatidylethanolamine PEG2000 (DPPE-PEG2000), (purchased from 
Avanti Polar Lipids, Alabaster, AL) were dissolved in chloroform and mixed in a round 
bottom flask in a 60:35:5 molar ratio of DPPC:cholesterol:DPPE-PEG2000. The mixture 
was heated to 60 °C and dried into a thin film under a stream of argon. The lipids were 
placed under vacuum overnight to remove residual chloroform. The lipid film was hydrated 
with TBSE buffer with 2 mM calcein (10 mM Tris Base, 150 mM NaCl, 1 mM EDTA, 2 mM 
calcein pH 7.4) at a 40 mM lipid concentration and heated at 60 °C for 15 min. The 
liposomes were collected and freeze-thawed 5 times with liquid nitrogen and a 60 °C 
waterbath. Following the freeze thaw, the liposomes were extruded 21 times though a 100 
nm membrane (LiposoFast extruder, Avestin, Ottawa, ON, Canada). The unincorporated 
calcein dye was removed through dialysis with a 50,000 MWCO dialysis membrane. A 
phosphorus assay was used to measure the lipid concentration of the liposomes as 
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described elsewhere.192 The liposomes were functionalized with the 3’ T10-FKN-S2 
amphiphile by the post insertion method. The liposomes (7.5 mM of lipids) and amphiphile 
(concentration varied from 0-50 µM) were incubated for 8 hr at 45 °C. Unincorporated 
aptamer-amphiphile was removed by a sepharose CL-4B gel filtration column. The 
aptamer-amphiphile concentration was measured after purification by first precipitating the 
aptamer-amphiphile with an ethanol precipitation and then measuring the absorbance at 
260 nm. Mouse colon adenocarcinoma MCA-38 cells (donated by Professor Lance 
Augustin, University of Minnesota) were transfected with a pCAGG-Neo-fractalkine 
plasmid (provided by Professor Alan Fong, University of North Carolina-Chapel Hill) using 
X-tremeGENE 9 transfection reagent to express fractalkine. Two days after transfection 
the cells were cultured with media containing 500 μg/mL G418. Drug-resistance clones 
were picked and expanded to create a MCA-38.FKN cell line, with FKN expression 
confirmed after 4 weeks. The cells were grown in a T-75 tissue culture flask and 
maintained at 37 °C in a 5% CO2 atmosphere. The cell media (DMEM: Life Technologies, 
Carlsbad, CA ) was replaced every 2 days and the cells split once they reached 90% 
confluency. Prior to the binding experiment, the cells were seeded into a 12 well plate at 
5x105 cells per well and allowed to adhere for 24 hr. The liposomes added to the wells at 
200 µM total lipids in PBS buffer with 0.91 mM CaCl2 and 0.49 mM MgCl2 and incubated 
at 37 °C for 1 hr. Following incubation, the cells were washed three times and lysed by 
the addition of 0.5 mL of 5% Triton-X100 in TBSE buffer. Cell debris was removed by 
centrifugation and the fluorescence was quantified using a fluorescent plate reader (Biotek 
Synergy H1, Winooski, VT) at excitation/emission of 490/520 nm. 
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3.3 Results and discussion 
 
3.3.1 Radioactive competition binding assay 
To create the aptamer-amphiphile the aptamer headgroup must be conjugated to a 
hydrophobic tail either directly or via a spacer. We first evaluated the effect of conjugating 
a hydrophobic tail directly to the aptamer (no spacer was used; NoSPR) on its binding 
affinity for fractalkine. The C16 dialkyl tail was conjugated at either the 3’ or 5’ end of the 
aptamer and the amphiphile’s binding affinity for fractalkine was measured by a 
radioactive competition binding assay. In this assay, a varying concentration of an 
unlabeled competitor molecule, either aptamer or aptamer-amphiphile, was added to a 
constant concentration of free 32P radiolabeled FKN-S2 aptamer. At high concentrations 
the unlabeled competitor outcompetes the radiolabeled FKN-S2 aptamer for fractalkine 
binding sites reducing the measured radioactivity; at low competitor concentrations, the 
radiolabeled FKN-S2 aptamer primarily binds to fractalkine increasing the measured 
radioactivity. The IC50 is defined as the concentration at which both FKN-S2 and the 
competitor bind equally and quantifies the relative affinity between the FKN-S2 aptamer 
and the competitor molecule.  
 
The IC50 binding curves for the 3’-NoSPR-FKN-S2 (NoSPR tail conjugated to the 3’ end 
of the aptamer) and 5’-NoSPR-FKN-S2 (NoSPR tail conjugated to the 5’ end of the 
aptamer) amphiphiles are shown in Figure 3.2 and their IC50 values are given in Table 3.1. 
The binding curve of the free FKN-S2 aptamer is shown in black for comparison. 
Amphiphiles with an IC50 greater than that of the free FKN-S2 aptamer have lower affinity 
for fractalkine than the free aptamer and vice versa.   
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Figure 3.2: IC50 competition binding curves of the free FKN-S2 aptamer and FKN-S2 
aptamer-amphiphiles where the tail was conjugated either at the 3’ or 5’ end of the aptamer 
in the absence of any spacer (NoSPR). The data show the mean ± standard error of the 
mean (SEM) of at least 6 independent experiments (n ≥ 6) with a single repetition per 
experiment. 
 
 
Addition of the tail significantly reduced the affinity for fractalkine and the affinity reduction 
was orientation specific as shown in Table 3.1. The 3’-NoSPR-FKN-S2 amphiphile (IC50 
of 65.7 ± 3.5 nM) had a higher affinity than the 5’-NoSPR-FKN-S2 amphiphile (IC50 of 81.6 
± 6.6 nM) (p < 0.05), but both orientations had lower affinity than the free FKN-S2 aptamer 
(IC50 of 8.64 ± 0.28 nM). Future aptamer-amphiphiles were synthesized by conjugating 
the tails and spacers at the 3’ end of the aptamer since this aptamer orientation resulted 
in higher binding affinity-amphiphiles. 
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Table 3.1: IC50 values of the FKN-S2 aptamer and aptamer-amphiphiles. The affinities of 
the amphiphiles for fractalkine were measured by competitive binding assays. The lower 
the IC50 value, the higher the binding affinity of that molecule for fractalkine. IC50 values 
are reported as the mean ± SEM (n = 3-9). p-values from the Student’s t-test analysis of 
the IC50 data can be found in Table 3.2. 
 
 
 
 
Next, the effect of different spacers on the binding affinity of the aptamer-amphiphiles for 
fractalkine was tested. The amphiphiles were synthesized with either PEG, alkyl (poly-
carbon), or oligo thymine (oligo-T) spacers. Each spacer has different characteristics. The 
PEG spacer is hydrophilic and flexible, the poly-C spacer is hydrophobic, and the oligo-T 
spacer is negatively charged, flexible, and hydrophilic. The PEG8 (8 PEG repeats), C24 (24 
carbons long) and T10 (10 thymine nucleic acids) spacers have roughly identical lengths. 
Likewise, the PEG4, C12 and T5 spacers have approximately similar lengths. The binding 
curves of the 3’-NoSPR, 3’-PEG8, 3’-C24, and 3’-T10 FKN-S2 amphiphiles are shown in 
Figure 3.3A with the IC50 values shown in Table 3.1 (p-values from the Student’s t-test 
analysis of the IC50 data are given in Table 3.2). The 3’-NoSPR and 3’-C24 spacers had 
similar IC50 values of 65.7 ± 3.5 nM and 73.5 ± 5.6 nM respectively (p > 0.05). The 3’-
PEG8 amphiphile (IC50 of 47.5 ± 6.1 nM) showed improved affinity compared to the 3’-
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NoSPR amphiphile (p < 0.05). The best amphiphile was clearly the 3’-T10 (IC50 of 21.8 ± 
2.0 nM; p < 0.001 with respect to 3’-NoSPR). 
 
 
Table 3.2: IC50 p-values from the Student’s t-test analysis for the FKN-S2 aptamer and 
aptamer amphiphile binding experiments with fractalkine. The IC50 values are shown in 
Table 3.1 (n = 3-9). 
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Figure 3.3: (A) IC50 binding curves of the free FKN-S2 aptamer and 3’-FKN-S2-
amphiphiles with T10, PEG8, NoSPR and C24 spacers. (B) IC50 binding curves of the free 
FKN-S2 aptamer and 3’-FKN-S2-amphiphiles with T10, T5 and A10 spacers and 5’-T10-FKN-
S2 amphiphile. Data are shown as the mean ± SEM of at least 6 independent experiments 
(n ≥ 6). 
 
 
The spacer length had a limited effect on the affinity of some amphiphiles (binding curves 
are shown in Figure 3.4, the IC50 values are given in Table 3.1 and the p-values from the 
Student’s t-test analysis of the IC50 data are given in Table 3.2). There was no difference 
between the C12 and C24 carbon spacers (p > 0.05). The affinity of the amphiphile improved 
from the 3’-PEG4 amphiphile, IC50 of 68.6 ± 7.1 nM, to the 3’-PEG8 amphiphile, 47.5 ± 6.1 
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nM, (p < 0.05), but there was no difference between the PEG8 and the PEG24 amphiphiles, 
49.6 ± 6.1 nM (p > 0.05). Longer oligo-T spacers seemed to improve the binding affinity 
of the amphiphiles for fractalkine. The 3’-T5 amphiphile had an IC50 of 37.6 ± 0.6 nM and 
the 3’-T10 amphiphile had an IC50 of 21.8 ± 2.0 nM (p < 0.001). 
 
 
 
 
Figure 3.4: IC50 binding curves for the (A) PEG spacer amphiphiles, (B) Carbon spacer 
amphiphiles, and (C) Poly-T spacer amphiphiles. The data show the mean ± SEM (n = 3 
- 9). 
 
 
Because the 3’-T10-FKN-S2 amphiphile was significantly better than the other amphiphiles, 
we tested the oligonucleotide derivatives 3’-T5-, 5’-T10-, and 3’-A10-FKN-S2 amphiphiles. 
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The 3’-T5-FKN-S2 amphiphile tested the effect of the oligonucleotide length, the 5’-T10-
FKN-S2 tested the effect of the aptamer orientation and the 3’-A10-FKN-S2 amphiphile 
tested the effect of the oligonucleotide spacer composition. The binding curves are shown 
in Figure 3.3B. The 5’-T10-FKN-S2 amphiphile (IC50 of 55.1 ± 4.9 nM) performed 
significantly worse (p < 0.05) than the 3’-T10-FKN-S2 amphiphile (IC50 of 21.8 ± 2.0 nM). 
This is consistent with the preferred 3’ aptamer orientation observed when the aptamer 
was conjugated directly to the tail in the absence of any spacer (3’-NoSPR-FKN-S2 
amphiphile shown in Figure 3.3A). Reducing the oligo-T spacer from 10 to 5 nucleotides 
significantly reduced the amphiphile affinity. The IC50 value was 21.8 ± 2.0 nM for the 3’-
T10-FKN-S2 amphiphile versus 37.6 ± 0.6 nM for 3’-T5-FKN-S2 (p < 0.001). The PEG and 
oligo-T IC50 data suggest that for short spacers, like PEG4 and T5, increasing spacer length 
increases affinity, but for spacers longer than the PEG8 no additional gains in affinity were 
observed. The 3’-A10-FKN-S2 amphiphile, IC50 of 24.8 ± 2.0 nM, performed equally well 
as the 3’-T10-FKN-S2 amphiphile (p > 0.05) suggesting that the nucleotide composition 
does not affect the affinity. 
 
The oligonucleotide spacer amphiphiles had higher affinities for fractalkine than the PEG 
or poly-carbon spacers but the reason for this improvement was uncertain. The 
improvement in affinity could be the result of the oligonucleotide spacer increasing the 
affinity of the FKN-S2 free aptamer. To test this, the IC50 values of 3’-T5-FKN-S2 and 3’-
T10-FKN-S2 free aptamers were measured. These aptamers were synthesized as the free 
aptamer plus the 3’ oligonucleotide spacers without the tails. The binding curves are 
shown in Figure 3.5. Interestingly, both the 3’-T5- FKN-S2 (IC50 of 3.4 ± 0.6 nM) and the 
3’-T10-FKN-S2 (IC50 of 3.6 ± 0.9 nM) free aptamers had a higher affinity for fractalkine than 
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the free FKN-S2 aptamer (IC50 of 8.64 ± 0.28 nM; p < 0.001 for both 3’-T5- FKN-S2 and 
3’-T10-FKN-S2 with respect to FKN-S2 aptamer). As shown in Table 3.2 there was no 
difference between the 3’-T5-FKN-S2 and 3’-T10-FKN-S2 free aptamers (p > 0.05). 
Because there is no difference in the affinity of the 3’-T5-FKN-S2 and 3’-T10-FKN-S2 free 
aptamers, the difference in the affinity of the respective amphiphiles is due to increased 
spacer lengths between the headgroup and the tail. 
 
 
 
 
Figure 3.5: IC50 binding curves for the oligo-T FKN-S2 free aptamers. There was no 
statistical difference between the T5 and T10 aptamers (p > 0.05). The data show the mean 
± SEM (n ≥ 6). 
 
 
3.3.2 Critical micelle concentration of aptamer-amphiphiles 
DNA-amphiphiles have been found to self-assemble into supramolecular structures like 
micelles. We used the Nile red assay to confirm self-assembly of the FKN-S2 amphiphiles 
and to measure their CMCs. The Nile red dye fluorescence is much greater in a lyophobic 
environment than in aqueous solution. At the CMC, when the amphiphiles form micelles, 
the dye partitions into the hydrophobic micelle core, which results in an increase in 
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fluorescence. Figure 3.6 shows a plot of Nile red fluorescence versus aptamer-amphiphile 
concentration for the 3’-NoSPR-, 3’-PEG8, 3’-C24, and 3’-T10-FKN-S2 amphiphiles. The 
fluorescence increases above background levels around 50 nM for each of the 
amphiphiles, suggesting they have similar CMCs despite differences in the 
hydrophobicities of the spacers used to synthesize the amphiphiles. However, due to the 
lack of sensitivity of the Nile red assay the CMC of 50 nM should be viewed as an upper 
limit, which means the different spacer amphiphiles might have differing CMCs but the 
assay is not sensitive enough to distinguish. The aptamer-amphiphile CMC is one to two 
orders of magnitude lower than that of peptide-amphiphiles with similar tails. Dialkyl tail 
peptide-amphiphiles typically have a CMC in the μM range for peptides.193-195 However, 
similar CMCs in the nM range are seen for other aptamer-amphiphiles.177, 183 
 
 
 
 
Figure 3.6: CMC curves of 3’-FKN-S2 amphiphiles with different spacers. The insert is 
zoomed in for a clearer view of the baseline (dotted line). The data show the mean ± SEM 
of 3 independent experiments (n = 3). 
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3.2.3 Circular dichroism spectroscopy  
The secondary structure of the aptamer may be significantly different in the micelle than 
when free in solution. Micelles can cause unfavorable base pairing between 
oligonucleotides, for example, forcing parallel-strand duplex formation between oligo(dA) 
and oligo(dT).196 Aptamer-aptamer interactions within a micelle may affect the structure 
and therefore the binding of the aptamers. Aptamers can adopt a variety of secondary 
structures including the standard B-form DNA and G-quadruplexes that can be probed 
using CD. B-form DNA forms from the standard Watson-Crick base pairing between two 
strands of complimentary DNA or within one strand forming stem-loop structures as shown 
in Figure 3.7A. G-quadruplexes are more complex. A G-quadruplex is a tertiary DNA 
structure composed of stacked G-quartets that form from the general sequence of 
GyXiGyXjGyXkGy, where X can be any nucleotide including guanine, y is at least 2, and i, j, 
k are integers greater than zero.197 A G-quartet is made up of four guanine nucleic acids 
arranged in a square, planar geometry stabilized by Hoogsteen hydrogen bonds. G-
quartets stack due to π bond stacking forming the helical G-quadruplex structure.69 While 
G-quadruplexes can form in pure water,198 small cations, in particular, K+ and to a lesser 
extent Na+, stabilize the formation by fitting inside and between the G-quartets 
coordinating with the oxygen of guanine.71 G-quadruplexes can be either parallel or anti-
parallel depending on strand orientation as shown in Figure 3.7B and 3.7C.69 In a parallel 
G-quadruplex all the strands share the same 5’ to 3’ orientation; in an anti-parallel G-
quadruplex the strands are orientated in the opposing 5’ to 3’ and the 3’ to 5’ direction. 
The G-quadruplex can be either intramolecular (unimolecular) composed of a single 
aptamer, or intermolecular composed of two (bimolecular) or four (tetramolecular) 
strands.70 
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Figure 3.7: (A) Structure of a stem-loop, (B) intramolecular parallel G-quadruplex and (C) 
intramolecular anti-parallel G-quadruplex. 
 
 
 
CD spectroscopy was used to probe the secondary structure of the free FKN-S2 aptamer 
and FKN-S2 amphiphiles. The CD spectra for the free FKN-S2 aptamer was measured in 
pure water, 20 mM KCl, and PBS buffer (Figure 3.8A). The water spectrum of FKN-S2 
had positive peaks at 285, 258, and 211 nm and a negative peak around 235 nm. The 258 
nm peak is characteristic of a parallel G-quadruplex, which typically has a positive peak 
between 258-265 nm, while the peak at 285 is characteristic of B-form DNA or a stem-
loop structure.73, 75, 80 The CD spectra in 20 mM KCl and PBS show a significant shift. The 
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addition of the salts greatly strengthened the G-quadruplex peak and shifted it to 263 nm, 
as the salts increase the CD signal of G-quadruplexes by stabilizing the structure.71, 199 
The stem-loop peak at 285 nm turned into a shoulder due to the strengthened G-
quadruplex peak, but it is still present. The spectrum in PBS buffer is similar in shape to 
the KCl spectrum but with slightly less signal strength. This is probably because PBS 
contains mostly Na+ which does not strengthen the G-quadruplex as strongly as K+.71 The 
G-quadruplex and stem-loop peaks in the spectrum suggest the presence of both in the 
aptamer structure. A hypothetical aptamer secondary structure is shown in Figure 3.8B 
where the first half of the aptamer, which is G rich, forms a G-quadruplex and the other 
half forms a stem-loop structure. 
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Figure 3.8: (A) CD spectra of 2.5 μM free FKN-S2 aptamer in water, 20 mM KCl and PBS. 
The data show the mean of four independent experiments (n = 4) with one replicate per 
experiment. (B) A hypothetical cartoon of the secondary structure of the FKN-S2 aptamer. 
The light orange represents the planes of the G-quartets. The G-quadruplex structure was 
predicted by the g-quadruplex prediction software QRS Mapper and the stem-loop 
structure was predicted by M-fold.200 
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3.3.4 Effect of the tail and spacer on the aptamer secondary structure 
The CD spectra of the aptamer-amphiphiles were taken in DI water and PBS (Figure 3.9). 
The 3’-PEG8-, 3’-C24-, and 3’-NoSPR-FKN-S2 spectra are nearly identical in water as 
shown in Figure- 3.9A. Positive peaks occur at 285, 257, and 210 nm and a negative peak 
occurs at 236 nm. There was no statistically significant difference in the peak intensity of 
the 3’-NoSPR, 3’-PEG8, and 3’-C24-FKN-S2 amphiphiles (n ≥ 4, p > 0.05) or the peak 
location indicating the secondary structure of the aptamer-amphiphile is similar between 
the different spacers in water. However, the 3’-T10-FKN-S2 amphiphile differs significantly 
from the other amphiphiles; it has a much stronger stem-loop peak, the peak has shifted 
to 281 nm, and a weaker G-quadruplex peak at 260 nm. 
 
The CD spectra of the 3’-NoSPR-, 3’-PEG8-, and 3’-C24-FKN-S2 amphiphiles in water 
(Figure 3.9A) were similar to in shape to the free FKN-S2 aptamer in water (Figure 3.8A) 
with the positive and negative peaks occurring at the same wavelengths. However, the G-
quadruplex peak at 257-258 nm is much stronger for the free FKN-S2 aptamer (2.7 
deg·cm2·dmol-1·10-5 versus ≈ 2.0 deg·cm2·dmol-1·10-5 for free FKN-S2 and the amphiphiles 
respectively; p < 0.01) suggesting that in water, the hydrophobic tails destabilize the G-
quadruplex. There was no difference in intensity of the other spectra peaks. Comparing 
the 3’-T10-FKN-S2 amphiphile and the free FKN-S2 aptamer, the 3’-T10 amphiphile had a 
more negative minimum at 236 nm, a depressed peak at 260 nm and a more intense peak 
at 281 nm (p < 0.01 for all peaks) than the free FKN-S2 aptamer. This suggests the 3’-T10 
amphiphile destabilizes the G-quadruplex and stabilizes the stem-loop. 
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Figure 3.9: (A) CD spectra of 2.5 μM 3’-FKN-S2-amphiphiles in water at 22 °C. The data 
show the mean of at least 4 independent experiments (n ≥ 4). (B) CD spectra of 2.5 μM 
3’-FKN-S2-amphiphiles in PBS at 22 °C. The data show the mean (n = 4). 
 
 
The spectra of the aptamer-amphiphiles in PBS are shown in Figure 3.9B. There is no 
statistical difference between the peaks of the 3’-NoSPR, 3’-PEG8, and 3’-C24-FKN-S2 
amphiphile spectra (p > 0.05). The spectra were strongly characteristic of a parallel G-
quadruplex with positive peaks at 262 nm and 206 nm and a negative peak at 241 nm. 
The 3’-T10-FKN-S2 amphiphile spectrum has similar characteristics but is slightly different 
from the other amphiphiles. The G-quadruplex peak shifts to 264 nm and is less intense. 
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Comparing the CD spectra of the aptamer-amphiphiles in water and PBS (Figure 3.9A 
and 3.9B respectively), the PBS buffer shifted the G-quadruplex peak from 257 nm to 262 
nm and increases the intensity 5 fold. This was expected because the K+ ions of the buffer 
can stabilize G-quadruplexes. Surprisingly, the stem-loop peak at 285 nm was not present 
in the aptamer-amphiphile CD spectra in PBS. The 3’-T10-FKN-S2 spectrum broadens 
slightly at 285 nm but no peak or shoulder was seen. It is possible the stem-loop is still 
present in the aptamer-amphiphiles, but the signal is hidden by the large G-quadruplex 
peak. 
 
The 3’-FKN-S2 amphiphiles and the free FKN-S2 aptamer CD spectra were similar in PBS 
except for a large change in the b-form shoulder at 285 nm. The peaks occurred at the 
same wavelengths and the shape was similar. However, the amphiphiles had a much 
stronger G-quadruplex peak at 262 nm (p < 0.01) than the free aptamer indicating that the 
addition of the tails stabilized the G-quadruplexes when dissolved in PBS. This was 
surprising given that the addition of tails seemed to destabilize the G-quadruplex when 
dissolved in pure water as described earlier. The difference may be due to the ability of 
PBS to screen the electrostatic repulsion from the negatively charged phosphate 
backbone. The charge screening of the PBS may promote the G-quadruplex structure that 
would otherwise be discouraged when the amphiphiles are dissolved in pure water due to 
electrostatic repulsion. 
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3.3.5 Melting curves  
Thermal melting studies were performed to further characterize the aptamer and 
amphiphiles. All melting experiments were done in PBS buffer after we attempted melting 
experiments in pure water but found the aptamer rapidly degraded at high temperatures, 
likely through depurination, because of the lack of salts.201 The G-quadruplex folding was 
monitored by CD at 265 nm and the stem-loop at 285 nm. Molar ellipticity was monitored 
instead of absorbance because the large signal change in CD between unfolded and 
folded conformations allowed for lower aptamer concentrations. The heating and melting 
curves of the free aptamer, shown in Figure 3.10, overlap indicating reversible melting. 
 
 
 
Figure 3.10: CD melting curves of 2.5 μM FKN-S2 free aptamer in PBS at (A) 265 nm and 
(B) 285 nm. The aptamer was heated to 95 °C and cooled to 25 °C at 0.25 °C/min followed 
by heating to 95 °C. Results show the mean molar ellipticity at each temperature from 4 
independent experiments (n = 4). 
 
 
The melting temperature (Tm) was measured as a function of the aptamer concentration 
to determine the molecularity of the aptamer (Figure 3.11). The melting temperature of 
unimolecular G-quadruplexes are concentration independent, but the melting temperature 
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of bimolecular and tetramolecular quadruplexes increase with increasing concentration.190 
The FKN-S2 free aptamer Tm was measured over an aptamer concentration range of 0.25 
to 10 μM. The Tm was constant in the concentration range 0.25 μM to 2.5 μM (Figure 3.11; 
p > 0.05), but increased at concentrations greater than 2.5 μM. This suggests that at 
concentrations below 2.5 µM, the free FKN-S2 aptamer forms an intramolecular 
(unimolecular) G-quadruplex and at concentrations above 2.5 µM it forms an 
intermolecular G-quadruplex. A similar transition from intramolecular to intermolecular G-
quadruplex has been observed for another aptamer as well.202 All CD measurements were 
taken at 2.5 μM to ensure the aptamer is in unimolecular G-quadruplex.  
 
 
 
 
Figure 3.11: Plot of G-quadruplex melting temperature (Tm) versus the natural log of FKN-
S2 free aptamer concentration. The samples were ran at 0.25 °C/min and the melting of 
G-quadruplexe was monitored by CD at 265 nm. The lines show the linear regression of 
the Tm from 0.25 µM to 2.5 µM and from 2.5 µM to 10 µM. The data points are the mean 
± SEM of at least 3 independent experiments (n ≥ 3). 
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The thermodynamic stability of the aptamer was assessed by thermal melting 
experiments. The temperature was decreased at 0.25 °C per min from 95 to 25 °C (cooling 
curve) and then increased from 25 to 95 °C (heating curve). No hysteresis was seen at 
this temperature gradient (Figure 3.10) indicating the melting process is reversible and at 
equilibrium. This allows for calculation of the melting temperature Tm and thermodynamic 
parameters such as the van’t Hoff enthalpy, ∆H°vH, entropy, ∆S°, and Gibbs free energy, 
∆G°. Both ∆H°vH and ∆S° are model dependent. The analysis assumes two states, folded 
and unfolded, are present and that both states are in equilibrium at each temperature. It 
also assumes the entropy and enthalpy are independent of temperature.190 The 
thermodynamic parameters for the FKN-S2, 3’-T5-FKN-S2 and 3’-T10-FKN-S2 free 
aptamers are shown in Table 3.3. There was no difference between the G- quadruplex 
melting temperatures of the FKN-S2, 3’-T5-FKN-S2, and 3’-T10-FKN-S2 free aptamers (p 
> 0.05). However, there was a significant difference in the Gibbs free energy. The FKN-
S2 aptamer G-quadruplex was more stable (ΔG°37 of -13.6 ± 0.10 kJ/mol) than the 3’-T5-
FKN-S2 aptamer (ΔG°37 of -12.6 ± 0.14 kJ/mol; p < 0.01) and the 3’-T10-FKN-S2 aptamer 
(ΔG°37 of -12.7 ± 0.09 kJ/mol; p < 0.01). There was no statistical difference between 3’-T5 
and 3’-T10-FKN-S2 free aptamers; p > 0.05. Addition of the oligo-T spacer to the 3’ end 
decreased the stability of the G-quadruplex. Increasing the spacer length from T5 to T10 
did not decrease the stability further. 
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Table 3.3: Thermodynamic parameters of FKN-S2, 3’-T5-FKN-S2, and 3’-T10-FKN-S2 free 
aptamers. Results show the mean ± SEM from 4 independent experiments (n = 4). G-
quadruplex Thermodynamics: aMelting monitored at 265 nm. bMelting monitored at 285 
nm. 
 
 
 
The trend was similar for the stem-loop DNA peak. The melting temperature did not 
change (p > 0.05) but the stability of the stem-loop increases from a ΔG°37 of -21.8 ± 0.5 
kJ/mol for the free FKN-S2 to -24.2 ± 0.5 and -24.6 ± 0.7 kJ/mol for the 3’-T5 and 3’-T10-
FKN-S2 free aptamers respectively (p < 0.05). There was no significant difference 
between the 3’-T5 and 3’-T10-FKN-S2 free aptamers (p > 0.05). The oligo-T spacer 
increases the stability of the stem-loop, but increasing the spacer from T5 to T10 does not 
further increase the stability. 
 
The thermodynamics of the aptamer were consistent with the IC50 data (Table 3.1). The 
binding curves of the 3’-T5 and 3’-T10-FKN-S2 free aptamers (Figure 3.5) were identical 
and so was the stability of the G-quadruplex and stem-loop secondary structures based 
on ∆G°37 (Table 3.3). Based on the ∆G°37 data from Table 3.3 for the FKN-S2 free aptamer, 
the G-quadruplex is more stable and the stem-loop less stable compared to the oligo-T 
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FKN-S2 free aptamers. This may suggest that destabilizing the G-quadruplex and 
stabilizing the stem-loop results in higher affinity of the free aptamer. 
 
The melting curves of the aptamer-amphiphiles were also measured, but they failed to 
produce usable data (Figure 3.12). The melting curves did not plateau at high or low 
temperatures and the signal intensity did not change much from low temperature to high 
temperature. Other lipid-oligonucleotide melting curves have shown similar results.203, 204 
The aptamer-amphiphiles retained the G-quadruplex secondary structure even at 95 °C 
based on CD spectra at various temperatures (Figure 3.13). However, no G-quadruplex 
peak was seen in the FKN-S2 aptamer spectra at 95°C (Figure 3.14). Even at 75 °C there 
is only a small G-quadruplex peak present (Figure 3.14) which is consistent with the 
melting curves for the FKN-S2 free aptamer (Figure 3.10A). It appears that the G-
quadruplex formation is stabilized when the amphiphiles are in a micellar structure. From 
the thermal melting experiments (Figure 3.11) we know that the FKN-S2 free aptamer 
forms bimolecular or tetramolecular G-quadruplexes at high concentrations. In the micelle 
headgroup corona layer, the concentration of the aptamer is much higher than in solution 
because the aptamer is confined at the surface of the micelle. Simple size arguments 
show the aptamer concentration within the micelle is much higher than 10 μM. The 
minimum possible aptamer concentration within a micelle would occur when the aptamer 
is fully stretched (approximately 19 nm assuming 0.34 nm/base and a 3 nm tail) and the 
micelle has an aggregation number of 2. The aptamer concentration in a micelle with these 
parameters is approximately 100 µM so it is likely that the FKN-S2 aptamer headgroup is 
forming intermolecular G-quadruplexes within the micelle. Thus, the high concentration of 
the aptamer headgroups in the micelles likely favors parallel intermolecular G-quadruplex 
  80 
formation, that may be responsible for the increased melting temperature, and may be 
more stable than the intramolecular parallel G-quadruplexes seen for the free aptamers.   
 
 
 
 
Figure 3.12: Melting curves of FKN-S2 amphiphiles measured by CD at 265 nm for the 
(A) 3’-NoSPR-FKN-S2 amphiphile, (B) 3’-PEG8-FKN-S2 amphiphile, (C) 3’- C24-FKN-S2 
amphiphile, and (D) 3’-T10-FKN-S2 amphiphiles. All melting curves are done in PBS with 
2.5 μM aptamer concentration. There is a decrease in signal with temperature indicating 
the G-quadruplex is denaturing, but the signal does not plateau at high or low 
temperatures like the FKN-S2 aptamer. 
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Figure 3.13: CD spectra of (A) 3’-NoSPR-FKN-S2 amphiphile, (B) 3’-PEG8-FKN-S2 
amphiphile, (C) 3’-C24-FKN-S2 amphiphile, and (D) 3’-T10-FKN-S2 amphiphile in PBS at 
different temperatures. The aptamer-amphiphile sample, 2.5 μM aptamer-amphiphile in 
PBS buffer, was heated to 25 °C, 50 °C, 75 °C, and 95 °C and the spectra were taken 
after a 5 minute temperature equilibrium period. 
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Figure 3.14: CD spectra of 2.5 μM FKN-S2 free aptamer in PBS at different temperatures. 
The aptamer-amphiphile sample was heated to 25 °C, 50 °C, 75 °C, and 95 °C and the 
spectra were taken after a 5 minute temperature equilibrium period. 
 
 
3.3.6 Cryo TEM of aptamer-amphiphiles 
The CMC experiments showed the presence of supramolecular structures. Cryo-TEM 
images of the FKN-S2 amphiphiles were taken to investigate the shape of the structures 
(Figure 3.15). The FKN-S2 amphiphiles formed both globular micelles and nanotapes with 
the majority of the structures being globular micelles. The micelles were found in all the 
samples and were roughly 10-20 nm in diameter. The nanotape structures were confirmed 
by tilting the TEM stage at different angles (representative images are shown for the 3’-
C24-FKN-S2 amphiphile in Figure 3.16). The nanotapes were both flat, Figure 3.15D, and 
twisted (Figure 3.15A-C). Flat and twisted structures were seen in all amphiphiles with 
similar frequency and the spacer had little effect on the shape of the nanotapes. However, 
the nanotapes were less prevalent in the 3’-T10-FKN-S2 amphiphile compared to the other 
spacer amphiphiles.   
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Figure 3.15: Cryo-TEM images of 3’-C24-FKN-S2 amphiphile nanotapes at (A) +30° 
stage tilt, (B) 0° stage tilt, and (C) -45° stage tilt. The images show twisted nanotapes. 
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Even though only micelles were seen in other studies with aptamer-amphiphiles,177, 183 
similar nanotapes were formed by sugar-amphiphiles,205 or peptide-amphiphiles with 
strong hydrogen bonding between the peptide headgroups,206, 207 and nucleic acid-
amphiphiles.208, 209 The nucleic acid-amphiphiles though that formed nanotape structures 
all had small headgroups consisting of a single nucleotide and a 12 carbon dialkyl tail.208, 
209 
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Figure 3.16: Cryo-TEM images of (A) 3’-NoSPR-FKN-S2 amphiphiles, (B) 3’-PEG8-FKN-
S2 amphiphiles, (C) 3’-C24-FKN-S2 amphiphiles, and (D) 3’-T10-FKN-S2 amphiphiles. All 
cryo-TEM samples were prepared from stock aptamer-amphiphile at 500 µM in water. 
 
 
Work by our group has showed recently that aptamer-amphiphiles can self-assemble into 
micelles and long nanotapes that are bilayer structures and can be flat or twisted.185 The 
25 nucleic acid aptamer used in that study (Muc-1 aptamer) had a stem-loop secondary 
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structure (with the potential to form G-quadruplexes as it had guanine nucleotides in its 
sequence) and was conjugated at its 5’ end to C16 dialkyl tails in the absence and presence 
of different spacers. The aptamer-amphiphiles with NoSPR or PEG spacers self-
assembled into micelles and the assembly process did not significantly alter the secondary 
structure of the aptamer headgroups as the amphiphiles also had a stem-loop secondary 
structure. However, in the presence of poly-C spacers the amphiphiles self-assembled 
into micelles and nanotapes, flat or twisted, with a G-quadruplex intermolecular secondary 
structure.185 We hypothesized that the hydrophobic attractions between the poly-C 
spacers brought the aptamer headgroups together, thus reducing the aptamer headgroup 
area at the interface and allowing the nanotapes to assemble. 
 
In the current study we found that in water FKN-S2 assumes a stem-loop and G-
quadruplex secondary structure as a free aptamer (Figure 3.8) and as an amphiphile 
(Figure 3.9A), independent of the type of spacer used. Furthermore, from the thermal 
melting studies we postulated that it is possible for the FKN-S2 aptamer headgroup to 
form intermolecular G-quadruplexes within the self-assembled structures. Therefore, 
these interactions between adjacent aptamer headgroups could be reducing the 
headgroup area and favoring the assembly of bilayer nanotapes, similar to the ones 
observed with the Muc-1 aptamer-amphiphile in the presence of poly-C spacers.  
 
To test this, we synthesized a 40-mer single-stranded DNA (ssDNA) sequence containing 
no guanine nucleotides (named NoG) thus eliminating the possibility of G-quadruplex 
formation. The NoG ssDNA had the following sequence, 5’-
TTCTATTCTCACATTTCATCTATTAAACCACCAATTAATT-amino C6 linker-3’. The 
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sequence was randomly generated from equal probabilities of A, C, and T nucleotides. 
The 3’-NoSPR-NoG amphiphile and 3’-C24-NoG amphiphile were synthesized and imaged 
via cryo-TEM (Figure 3.17). The 3’-NoSPR-NoG amphiphile did not form nanotapes while 
the 3’-C24-NoG amphiphile formed micelles and flat and twisted nanotapes. This is 
consistent with the findings of our previous study with the Muc-1 aptamer-amphiphile.185 
Because the NoG ssDNA headgroup does not form intermolecular G-quadruplexes, the 
3’-NoSPR-NoG amphiphile does not form nanotapes in the absence of either a G-
quadruplex secondary structure or a hydrophobic poly-C spacer that will reduce the 
aptamer headroup area by driving the aptamer headgroups in close proximity and allowing 
the nanotapes to form. 
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Figure 3.17: Cryo TEM images of (A) 3’-NoSPR-NoG amphiphile and (B) 3’-C24-NoG 
amphiphile. 
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To assess our hypothesis even further we used a ssDNA sequence, named (GGGT)3, that 
can form G-quadruplexes. The (GGGT)3 ssDNA with the following sequence, 5’-
TTCTATTCTCAC ATTTCATCTATTAAACCGGGTGGGTGGG-amino C6 linker-3’, was 
identical to the NoG ssDNA sequence except that 11 nucleotides at the 3’ end were 
replaced with the GGGT repeat where a thymine nucleic acid separated 3 consecutive 
guanines. The 3’ terminal thymine was not included because it was unlikely to participate 
in G-quadruplex formation. The (GGGT)3 ssDNA sequence cannot form an intramolecular 
G-quadruplex but is capable of forming intermolecular G-quadruplexes. The CD spectra 
of the (GGGT)3 free ssDNA, the 3’-NoSPR-(GGGT)3 amphiphile, and 3’-C24-(GGGT)3 
amphiphile are shown in Figure 3.18. The (GGGT)3 free ssDNA does not form G-
quadruplexes, but the 3’NoSPR-(GGGT)3 and 3’-C24-(GGGT)3 amphiphiles do. Figure 
3.19 shows cryo-TEM images of the amphiphiles. Both the 3’NoSPR-(GGGT)3 and 3’-C24-
(GGGT)3 amphiphiles form nanotape structures. In this case, we hypothesize that the 
intermolecular G-quadruplex formation reduces the headgroup area thus allowing for the 
assembly of the nanotapes. 
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Figure 3.18: CD spectra of the (GGGT)3 free ssDNA and amphiphiles in PBS at 22 °C 
and 2.5 µM concentration. All samples were heat denatured in a 95 °C heating block for 5 
min followed by rapid cooling to room temperature. 
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Figure 3.19: Cryo TEM images of (A) 3’-NoSPR-(GGGT)3 amphiphile and (B) 3’-C24-
(GGGT)3 amphiphile. 
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3.3.7 Binding of 3’-T10-FKN-S2 functionalized liposomes 
The aptamers are well suited for targeted drug delivery applications because they are 
considered to be non-immunogenic, have high affinity and specificity, and can be used to 
functionalize drug delivery vehicles.174 There are a range of drug delivery vehicles from 
polymersomes, dendrimers, nanoparticles, liposomes, and micelles.174 As a proof of 
concept, we functionalized stealth liposomes (liposomes functionalized with PEG) with the 
3’-T10-FKN-S2 amphiphile and targeted them to fractalkine expressing cancer cells. 
Liposomes were the drug delivery vehicle of choice because they are well studied and 
characterized, and the hydrophobic tail of the aptamer-amphiphile will spontaneously 
incorporate into the liposome bilayer. The liposomes were prepared with 5 mol% DPPE-
PEG2000 to confer stealth properties to the liposomes. The PEG2000 coating reduces 
non-specific interactions with surfaces, proteins, and cells by providing a steric barrier to 
protein adsorption and cell adhesion.191 The liposomes were functionalized with the 3’-T10-
FKN-S2 amphiphile because the IC50 binding experiments (Table 3.1) showed it had the 
highest affinity for fractalkine. The aptamer-amphiphile was incorporated into the 
liposomes using the post insertion method. On average, 79% of the aptamer-amphiphiles 
incorporated into the liposomes and all of the amphiphiles were on the outside of the 
liposomes because the liposomes were fully formed before addition of the amphiphile. The 
amount of amphiphile functionalization was controlled by changing the amount of 
amphiphile added to the liposomes during the post insertion step as shown in Figure 3.20.   
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Figure 3.20: Liposome functionalization curve for the 3’-T10-FKN-S2 amphiphile. The data 
show the mean ± SEM (n = 3). 
 
 
The 3’-T10-FKN-S2 functionalized stealth liposomes were loaded with the calcein dye and 
incubated with MCA-38.FKN mouse colon adenocarcinoma cells transfected to express 
fractalkine (fractalkine expression levels shown in Figure 3.21). The liposomes were 
incubated for 1 hr at 37 °C and the amount of binding and internalization was quantified 
using fluorescence as shown in Figure 3.22. 
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Figure 3.21: Fractalkine expression on MCA-38.FKN cells. 2 x 105 MCA-38.FKN cells 
were suspended in 200 µL of PBS buffer and 2.5 µg/mL of anti-fractalkine antibody (Cat 
No. AF365, R&D Systems, Minneapolis, MN) were added. After a 30 min incubation at 4 
°C, the cells were centrifuged and suspended in 200 µL of PBS with a secondary antibody 
(Cat No. F0109, R&D Systems, Minneapolis, MN) at the concentration recommended by 
the manufacturer. The secondary antibody was incubated for 30 min at 4 °C and the cells 
were washed twice by centrifugation and imaged by flow cytometry (BD FACSCalibur, 
University Flow Cytometry Resource, University of Minnesota, Minneapolis, MN). 
 
 
  95 
 
 
Figure 3.22: Liposome binding and internalization to fractalkine expressing MCA-38.FKN 
cells as a function of the concentration of the 3’-T10-FKN-S2 amphiphile used to 
functionalize the stealth liposomes. Fluorescent liposomes were incubated with the cells 
for 1 hr at 37 °C and the binding and internalization was quantified by fluorescence. The 
data show the mean ± SEM (n = 4). Two tailed t-test with unequal variances was used to 
determine significance, †p > 0.05, *p < 0.05. 
 
 
The 3’-T10-FKN-S2 amphiphile functionalized stealth liposomes bound to the cells at all 
amphiphile concentrations tested (p < 0.05). The binding increased with increasing 
aptamer functionalization. This is expected because liposomes with more aptamers will 
likely bind with greater avidity due to multiple receptor-ligand interactions. A binding 
plateaued starting around 0.28 mol% aptamer-amphiphile was observed and may be a 
result of the liposome-fractalkine binding reaching a saturation point. This experiment 
showed that using the 3’-T10-FKN-S2 amphiphile to functionalize stealth liposomes for 
targeted drug delivery applications is feasible and warrants further investigation in the 
future. 
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3.4 Conclusions 
In this study we synthesized FKN-S2 aptamer-amphiphiles with different spacers and 
investigated their binding to fractalkine, their secondary structure and self-assembly. The 
addition of the tail to the aptamer reduced the affinity of FKN-S2 aptamer for fractalkine 
for all spacer-tail combinations tested. However, the 3’-T10-FKN-S2 amphiphile had a 
much higher binding affinity than the other amphiphiles because of the improved affinity 
of the free 3’-T10-FKN-S2 aptamer for fractalkine caused by the oligo-T spacer. Melting 
curve analysis showed that the oligo-T spacer increased the ΔG°37, thus decreasing 
stability of the G-quadruplex while increasing the stability of the stem-loop. The CMCs of 
the FKN-S2 aptamer-amphiphiles were less than 50 nM and all the FKN-S2 amphiphiles 
self-assembled into globular micelles and nanotapes, flat or twisted. For the 40-mer 
ssDNA sequences investigated here, nanotapes were observed in two different cases. In 
the first case, nanotapes formed from the FKN-S2 and (GGGT)3 NoSPR amphiphiles 
because of the strong intermolecular G-quadruplex interactions between the ssDNA 
headgroups. In the second case, nanotapes did not form in the NoG-NoSPR amphiphles 
because the ssDNA headgroup could not form G-quadruplexes. The nanotapes only 
formed in the presence of a hydrophobic poly-carbon spacer. We therefore hypothesized, 
that in both cases, whether the driving force was the attractive interactions between the 
ssDNA headgroups or the attractive interactions between the hydrophobic spacers, the 
aptamer headroups were brought in close proximity, thus reducing the area per aptamer 
at the interface allowing the nanotape assemblies to form. Finally, we showed that stealth 
liposomes functionalized with the FKN-S2 amphiphile were able to bind to fractalkine 
expressing cells. Further research into the properties of ssDNA nanotapes could lead to 
tunable self-assembled aptamer-amphiphiles with molecular recognition properties which 
can be used for bottom up assembly, targeted drug delivery, and sensors.  
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4 Conclusion 
Aptamers are an exciting and underdeveloped tool with an array of potential applications 
ranging from diagnostic tests and sensors to drug delivery and therapeutics. The research 
in this thesis was performed with the intention of developing aptamer based therapeutics 
against the cellular protein fractalkine. Fractalkine is expressed at sites of infection and 
inflammation to recruit and capture leukocytes. Because fractalkine is involved heavily 
with the inflammatory response, it plays a role in a variety of diseases including cancer, 
atherosclerosis, asthma, and arthritis. Currently there are no therapeutic agents that target 
fractalkine.95 Fractalkine’s structure, function, and role in disease make it an intriguing 
target for therapeutic applications. 
 
In this work, an aptamer named FKN-S2 was developed that binds fractalkine with high 
affinity and specificity. Development of the aptamer required creative solutions to 
problems encountered during the SELEX process. In particular, unique methods for the 
immobilization of fractalkine and counter selection steps enabled the selection of the FKN-
S2 aptamer where previous methods had failed. The FKN-S2 aptamer was modified by 
the addition of a hydrophobic tail, creating an aptamer-amphiphile. The aptamer-
amphiphile had a much lower affinity for fractalkine than the free aptamer. To improve the 
affinity, the aptamer-amphiphiles was modified by inserting a spacer molecule between 
the aptamer headgroup and the tail. An optimized aptamer-amphiphile was developed by 
changing the length and the nature of the spacer. PEG, poly carbon, and oligonucleotide 
spacers were synthesized and tested. A 10 nucleotide thymidine spacer significantly 
improved the affinity of the amphiphile. The aptamer-amphiphiles self-assembled into 
micelles and nanotapes and the properties of aptamer-amphiphile self-assembly was 
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probed using CD spectroscopy and cryo-TEM. Finally, the FKN-S2-amphihle was 
incorporated into a liposome and targeted to fractalkine expressing cells as a proof of 
concept drug delivery system. Future work will investigate the self-assembly properties 
and FKN-S2 based drug delivery vehicles for therapeutic applications. 
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